2011 Results
CANADIAN PAEDIATRIC SURVEILLANCE PROGRAM
Mission Statement

To contribute to the improvement of the health of children and youth in Canada by national surveillance and research into childhood disorders that are high in disability, morbidity, mortality and economic costs to society, despite their low frequency.
Public Health Impacts of CPSP Studies
2005 to 2011

Acquired demyelinating syndromes (ADS) of the central nervous system
• **Findings:** Optic neuritis was the most common presentation
• **Public health impact:** Supports the need for increased awareness that ADS could be a first manifestation of multiple sclerosis

Congenital myotonic dystrophy (CMD)
• **Findings:** Neonatal mortality rate of 18%; CMD being a disorder of muscle immaturity, complication-free prolonged ventilation can result in improvement in strength and hypotonia state
• **Public health impact:** Reinforces the need for greater awareness, screening in pregnancy and genetic counselling, as 58% were index cases for the families

Early-onset eating disorders
• **Findings:** Incidence of 2.6 per 100,000 children five to 12 years of age
• **Public health impact:** Supports CPS statement for use of growth charts to assist early detection

Head injury secondary to suspected child maltreatment
• **Findings:** High mortality rate of 12%; over half involved infants were less than six months of age
• **Public health impact:** Supports the need for more programs to prevent abusive head injuries

Injuries associated with baby products
• **Findings:** Strollers involved in 63% of the 90 reported incidents
• **Public health impact:** Supports Health Canada’s advisory warning about amputation/laceration hazard posed by strollers with hinge mechanisms

Medium-chain acyl-coenzyme A dehydrogenase deficiency
• **Findings:** High efficiency of newborn screening programs to detect asymptomatic patients
• **Public health impact:** Supports early detection to allow for simple preventive measures (e.g., avoidance of fasting, prompt management of acute illnesses)

Non-type 1 diabetes mellitus
• **Findings:** Number of new cases of paediatric type 2 diabetes was higher than expected; 95% were overweight/obese; important regional differences were identified
• **Public health impact:** Supports CPS and PHAC efforts in promoting healthy active living

Renal stone disease associated with melamine-contaminated products
• **Findings:** No cases found in Canada
• **Public health impact:** Demonstrates added value of the CPSP to conduct enhanced surveillance of emerging public health concerns, quickly and inexpensively

Severe iron-deficiency anemia (IDA)
• **Findings:** Nearly 200 confirmed cases, many with significant morbidity; risk factors included prolonged bottle-feeding and excessive cow’s milk intake
• **Public health impact:** Supports the need for nutrition counselling to prevent IDA

Travel-related illnesses in paediatric travellers who visit with friends and relatives abroad
• **Findings:** Enteric fever, malaria, diarrheal diseases and hepatitis A comprised 75% of the cases; most parents did not seek pre-travel advice
• **Public health impact:** Supports the need for education and provision of anticipatory guidance on pre-travel advice
# Table of Contents

Acknowledgements................................................................. 3
Funding.................................................................................. 3

Foreword................................................................................ 4
  Federal Minister of Health...................................................... 4
  Chief Public Health Officer of Canada................................. 4
  President of the Canadian Paediatric Society....................... 5
  CPSP Chair................................................................. 5

CPSP Steering Committee .................................................. 6
CPSP Working Group........................................................... 6

Publications 2007–2011......................................................... 7
  Published papers related to studies....................................... 7
  Highlights and Commentaries published in 2011 in *Paediatrics & Child Health* ............................................. 8

Presentations in 2011.......................................................... 9
  National............................................................................. 9
  International...................................................................... 9

Surveillance at Work .............................................................. 10
  Overview.......................................................................... 10
  Investigators’ corner............................................................ 11
  One-time survey questions............................................... 12

CPSP Principal Investigators ................................................. 13

Surveillance Studies in 2011 ................................................. 14
  Acute flaccid paralysis......................................................... 14
  Adrenal suppression........................................................... 17
  Adverse drug reactions – serious and life-threatening .......... 19
  Conversion disorder in children and youth ......................... 21
  Early-onset neonatal sepsis and meningitis......................... 22
  Langerhans cell histiocytosis............................................... 24
  Neonatal hyperbilirubinemia – severe (2011–2013) ................. 26
  Paediatric myasthenia (final report)...................................... 27
  Periodic fever syndromes..................................................... 29
  Persistent albuminuria in the paediatric population with type 2 diabetes mellitus ............................................ 30
  Respiratory syncytial virus infections in paediatric transplant patients......................................................... 32
  Severe iron-deficiency anemia in infants and young children (final report)........... 33
  Travel-related illnesses in paediatric travellers who visit friends and relatives abroad (final report) ................. 35

Survey Questions .................................................................. 38
  Accidental or intentional methadone exposure in children and young infants................................................... 38
  Behaviours and practices towards food allergies.................. 39
  CPSP resource use.............................................................. 40
  Complications associated with energy drinks .................... 41
  Necrotizing enterocolitis in infants...................................... 43
  Sudden unexplained death in children with epilepsy .......... 44

International Developments ............................................... 45
  2011 highlights ................................................................... 45
  Publications from INoPSU members .................................. 46

Research Opportunities – Call for New Studies ...................... 47
Acknowledgements

The key strength of the Canadian Paediatric Surveillance Program (CPSP) is its commitment to the improvement of the health of children and youth in Canada and around the world. This would not be possible without the participation of Canadian paediatricians, subspecialists and other health care providers in the monthly collection of information on rare paediatric conditions, principal investigators who design studies and analyze the data to provide knowledge and educational solutions, and the guidance of the Steering Committee members. We thank them all.

We also thank IMPACT (Immunization Monitoring Program ACTive) centres for their role in the verification of the acute flaccid paralysis study data collected and for their support of the CPSP.

The strong partnership between the Canadian Paediatric Society (CPS) and the Public Health Agency of Canada (PHAC) allows the program to grow in Canada and to take a leadership role on the international scene.

Funding

Funding for the CPSP is required to support program management. The surveillance program is funded through a combination of government funds and unrestricted grants from Canadian charities, research institutions, hospitals and corporations. All funding is provided to maintain and expand the program.

We gratefully acknowledge the financial support received in 2011 from the Public Health Agency of Canada, Health Canada’s Therapeutic Effectiveness and Policy Bureau, and the following non-governmental sources:

- Citizens United for Research in Epilepsy (CURE)
- IWK Health Centre Research Award Program
- New Investigator Fund, Hamilton Health Sciences 2011
- Novartis Pharmaceuticals Canada Inc.
- St. Michael’s Hospital AHSC AFP Innovation Fund
- Talecris Biotherapeutics
- The Hospital for Sick Children Foundation
- University of Alberta
Foreword

Federal Minister of Health

The Honourable Leona Aglukkaq

I would like to congratulate the Canadian Paediatric Society for its contribution to improving the health and well-being of children and youth in Canada. As outlined in this report, the Society successfully monitors rare diseases and conditions affecting our young people through the Canadian Paediatric Surveillance Program (CPSP).

With the help of over 2,500 paediatricians and paediatric subspecialists, the CPSP gathers valuable information that helps us understand how these rare diseases affect children and youth and how treatments are working. This information also gives us insight into risk factors, prevention practices and the types of health policies best suited to address the needs of patients with these conditions.

I believe the success of the CPSP is due in part to the strong partnership between the Public Health Agency of Canada, the Canadian Paediatric Society and paediatricians across Canada who take the time to provide information and ongoing support.

The Government of Canada is proud to work with the Canadian Paediatric Society and its members in providing a healthier future for Canadian children and youth.

Chief Public Health Officer of Canada

Dr. David Butler-Jones

As Chief Public Health Officer of Canada, I congratulate the Canadian Paediatric Surveillance Program on the accomplishments described in its 2011 annual report. The year 2011 marks the fifteenth anniversary of the CPSP, an occasion to acknowledge the program’s invaluable surveillance leadership role.

Through the CPSP, data on rare childhood diseases and conditions are collected monthly from more than 2,500 paediatricians, subspecialists and health care providers. This information helps us learn more about these diseases, determine what we can do to prevent them and decide what future health policies we need to consider.

I would like to thank the CPSP Steering Committee, Canadian Paediatric Society staff, the Public Health Agency of Canada staff and all the paediatricians for their steadfast commitment to the surveillance program. Their dedication and spirit of collaboration signify their commitment to helping the millions of children and youth in Canada and around the world who are living with a rare disease.
President of the Canadian Paediatric Society

Dr. Jean-Yves Frappier

As President of the CPS and as a founder of the Adolescent Medicine subspecialty at the Royal College of Physicians and Surgeons of Canada, I am very proud to be part of the CPSP and its achievements, both nationally and internationally. Through the CPSP, mental health issues affecting children and youth were studied, such as early-onset eating disorders, conversion disorder and the complications associated with the consumption of energy drinks.

The statistics of the CPSP’s first 15 years are impressive and include over 2,500 participants, 49 studies and 26 one-time surveys. These statistics confirm the continued interest and support of Canadian paediatricians and paediatric subspecialists. The 47 study-related publications in peer-reviewed journals, such as Paediatrics & Child Health, CMAJ, Pediatrics, Neurology and Diabetes, attest to the ongoing quality of the research conducted, as well as the productivity and visibility of the program.

The CPSP, in its leadership co-chair role of INoPSU, is very active in encouraging collaboration among investigators, in preparing comparative studies resulting in publications and in promoting the medical and public health importance of the network.

The CPS is looking forward to many more years of timely, important and pertinent national epidemiological research for the benefit of our Canadian children and youth.

CPSP Chair

Dr. Kimberly Dow

The Canadian Paediatric Surveillance Program, this year celebrating its fifteenth anniversary, continues to strive for improvement in the health of children and youth in Canada through excellence in national surveillance and research.

Over the years the CPSP has vastly reduced the amount of time from the inception of a study research idea on rare diseases to the completion of data collection and the presentation/publication of study results in many different fields of paediatrics. Innovative feedback measures such as educational resources, ADR Tips of the Month and CPSP Highlights and Commentaries in Paediatrics & Child Health, have been highly praised by program participants.

This year saw the launch of our online database, e-CPSP, a giant step in both going green and accelerating the collection of data. I would encourage you to read this year’s anniversary publication with special attention to study results, e-CPSP and the theme page on the impact of CPSP studies on public health.

Finally, I would like to thank all Canadian paediatricians who are contributing on a monthly basis to the success of our surveillance program. The program’s achievements over the past fifteen years would simply not be possible without your support.
In November 2011, Denis Daneman, Tom Wong, and Sandra Woods completed their terms as members of the CPSP Steering Committee. We sincerely thank them for their contributions over the past years.

### CPSP Steering Committee

<table>
<thead>
<tr>
<th>Name</th>
<th>Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kimberly Dow, MD</td>
<td>Canadian Paediatric Society</td>
</tr>
<tr>
<td>Claude Cyr, MD</td>
<td>Canadian Paediatric Society</td>
</tr>
<tr>
<td>Denis Daneman, MD</td>
<td>Paediatric Chairs of Canada</td>
</tr>
<tr>
<td>Marie Adèle Davis, MBA</td>
<td>Canadian Paediatric Society</td>
</tr>
<tr>
<td>Kevin Gordon, MD</td>
<td>Canadian Association of Child Neurology (Liaison)</td>
</tr>
<tr>
<td>Danielle Grenier, MD</td>
<td>Canadian Paediatric Society</td>
</tr>
<tr>
<td>W. James King, MD</td>
<td>Canadian Paediatric Society</td>
</tr>
<tr>
<td>Dorothy Moore, MD</td>
<td>IMPACT (Immunization Monitoring Program ACTive) (Liaison)</td>
</tr>
<tr>
<td>Paul Muirhead, LL.M.</td>
<td>Consultant</td>
</tr>
<tr>
<td>Alison Quartaro, BA</td>
<td>Canadian Paediatric Society</td>
</tr>
<tr>
<td>Jeff Scott, MD</td>
<td>Canadian Paediatric Society</td>
</tr>
<tr>
<td>Paul Thiessen, MD</td>
<td>Canadian Paediatric Society</td>
</tr>
<tr>
<td>Lesley Ann Turner, MD</td>
<td>Canadian College of Medical Geneticists (Liaison)</td>
</tr>
<tr>
<td>Anne-Marie Ugnat, PhD</td>
<td>Centre for Chronic Disease Prevention and Control, Public Health Agency of Canada</td>
</tr>
<tr>
<td>Tom Wong, MD</td>
<td>Centre for Communicable Diseases and Infection Control, Public Health Agency of Canada</td>
</tr>
<tr>
<td>Sandra Woods, MD</td>
<td>Canadian Paediatric Society</td>
</tr>
</tbody>
</table>

---

### CPSP Working Group

<table>
<thead>
<tr>
<th>Name</th>
<th>Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Danielle Grenier, MD (Chair)</td>
<td>Canadian Paediatric Society</td>
</tr>
<tr>
<td>Melanie Laffin Thibodeau, BCom (Chair until March)</td>
<td>Canadian Paediatric Society</td>
</tr>
<tr>
<td>Marie Adèle Davis, MBA</td>
<td>Canadian Paediatric Society</td>
</tr>
<tr>
<td>Laurence Gillieson, BA</td>
<td>Canadian Paediatric Society</td>
</tr>
<tr>
<td>Alison Quartaro, BA</td>
<td>Canadian Paediatric Society</td>
</tr>
<tr>
<td>Anne-Marie Ugnat, PhD</td>
<td>Centre for Chronic Disease Prevention and Control, Public Health Agency of Canada</td>
</tr>
</tbody>
</table>

---

CPSP 2011 RESULTS
Publications 2007–2011

Published papers related to studies
(See www.cps.ca/cpsp for a complete list of abstracts with hyperlinks.)

**Acquired demyelinating syndromes of the CNS**

**Acute flaccid paralysis**

**Child maltreatment**


**Complementary and alternative medicine**

**Congenital myotonic dystrophy**


**Congenital rubella syndrome**

**Early-onset eating disorders**

**Kernicterus / neonatal hyperbilirubinemia**


**Lap-belt syndrome**

**Necrotizing fasciitis**
Epidemiology and outcome of necrotizing fasciitis in children: An active surveillance study of the Canadian Paediatric Surveillance Program. Ihuoma E, Davies HD. *J Pediatr* 2007; 151(7): 79-84
Publications 2007-2011

Non-type 1 diabetes mellitus

Surveillance – General
Active surveillance: An essential tool in safeguarding the health and well-being of children and youth (Commentary). Grenier D. *CMAJ* 2007; 177(7): 169-71


Vitamin D deficiency rickets

CPSP Highlights and Commentaries published in 2011 in *Paediatrics & Child Health*
(See www.cps.ca/cpsp for a complete list with hyperlinks.)

Does active surveillance of serious and life-threatening adverse drug reactions improve reporting? Zimmerman M, Grenier D, Levitt M. *Paediatr Child Health* 2011; 16(9): 532-4

Early-onset neonatal sepsis: It is not only group B streptococcus. Sgro N, Yudin MH, Lee S, Sankaran K, Tran D, Campbell D. *Paediatr Child Health* 2011; 16(5): 269


What happens when you mix a transplant with respiratory syncytial virus? Robinson JL, Grenier D. *Paediatr Child Health* 2011; 16(1): 12
Presentations in 2011

(See www.cps.ca/cpsp for a complete list of presentations with hyperlinks.)

National

**Early-onset neonatal sepsis and meningitis**
Early-onset neonatal sepsis in industrialized countries. Sgro M. Global Health Symposium – Group B streptococcal sepsis in newborns: An international expert panel discussion on the global burden and opportunities for prevention, The Hospital for Sick Children, Toronto, in October (oral)

Neonatal sepsis and the changing patterns of infection. Sgro M. Paediatric Update Session. Canadian Paediatric Society Annual Conference, Quebec City, in June (oral)

**Kernicterus**
Chronic bilirubin encephalopathy continues to occur in Canada. Sgro M, Campbell D, Shah V. Canadian Paediatric Society Annual Conference, Quebec City, in June (oral)

**Paediatric myasthenia**
Paediatric myasthenia: first year of active national surveillance. Kolski H. 46th Annual Congress of the Canadian Neurological Sciences Federation, Vancouver, in June (oral)

**Severe iron-deficiency anemia in infants and young children**
The landscape of severe iron-deficiency anemia in Canada. Wong S. Paediatric Update Session, Canadian Paediatric Society Annual Conference, Quebec City, in June (oral)

**Surveillance – General**
Paediatric surveillance – A core medical and public health function. Grenier D, Davis MA. Children’s Hospital of Eastern Ontario, Ottawa, in June (oral)

Can active surveillance improve reporting of serious and life-threatening drug reactions? The Canadian experience. Grenier D, Davis MA, Zimmerman M, Laffin Thibodeau M. Canadian Paediatric Society Annual Conference, Quebec City, in June (posterior)

International

**Surveillance – General**
Taller de vigilancia epidemiológica pediatría. Grenier D, Mercer R. I Conferencia de Actualización en Pediatría – ALAPE 2011, Panama, in April (oral)

¿Una vigilancia estricta puede mejorar el reporte de reacciones adversas a medicamentos? Grenier D, Zimmerman M. XIII Congreso Nacional de Pediatria, CoNaPeMe, Guadalajara, in May (oral)


Does active surveillance of adverse drug reactions improve reporting? The CPSP experience. Grenier D, Zimmerman M. International Network of Paediatric Surveillance Units (INoPSU) Conference, Montreux, in September (oral)


Public Health Impacts of the International Network of Paediatric Surveillance Units. Grenier D. Congreso Nacional de Pediatria, Albufeira, in October (oral)

**Travel-related illnesses in paediatric travelers who visit friends and relatives abroad**
Surveillance at Work

Overview

The importance of surveillance to the practice of medicine cannot be overstated. Through the ongoing, systematic collection of data, the burden of disease can be determined, interventions to prevent the occurrence of a disorder can be assessed, and information collected can be used in the development of health policy. Surveillance takes research data into action.

According to Statistics Canada, in September 2011 the Canadian population was 34,482,779, and 7,841,284 individuals were 0–19 years, which represents approximately 23% of the Canadian population. Although individually uncommon, rare diseases affect thousands of these children and youth and typically have lifelong impacts. The actual incidence of many of these disorders is not readily available, and yet is essential for improved clinical care, advocacy and health service planning.

The CPSP provides an innovative means to undertake paediatric surveillance and increase awareness of childhood disorders that are high in disability, morbidity, mortality and economic cost to society, despite their low frequency. Preference is given to studies that have strong public health importance or could not be undertaken any other way. All studies in the program must conform to high standards of scientific rigour and practicality, and the CPSP assures the confidentiality of all information collected. To enhance data capture on individual studies, the program works collaboratively with other professional groups, such as psychiatrists, pathologists/coroners, and adult endocrinologists. The program also offers an opportunity for international collaboration, through the International Network of Paediatric Surveillance Units (INoPSU), with other paediatric surveillance units worldwide.

Process

The CPSP Steering Committee oversees the program and reviews new study proposals. Upon initiation of a new study, practising Canadian paediatricians, paediatric subspecialists and other health care providers receive a summary of the protocol, including the case definition and a brief description of the condition. This serves to educate and increase awareness of conditions under surveillance while providing a uniform basis for reporting. The CPSP uses a two-tiered reporting process to ascertain and investigate cases: an initial ‘check-off’ form and a detailed questionnaire. Case ascertainment is undertaken by comparing selected study results with cases reported to the Hospital Discharge Abstract database of the Canadian Institute of Health Information (CIHI) and by investigating duplicate reports and comparing data with relative programs or centres. To date, case ascertainment has been excellent.

Reporting

The ‘check-off’ form, listing the conditions currently under surveillance, is mailed monthly to participants. For each condition, respondents are asked to indicate the number of new cases seen in the last month, including ‘nil’ reports. A ‘nil’ report is very important in active surveillance; the CPSP cannot simply assume that no reply means no cases. In October 2011, the program launched eCPSP, an electronic platform giving participants the opportunity to receive their monthly forms online.

Participants report all cases meeting the case definitions, including suspect or probable cases. This sometimes leads to duplicate reports but avoids missed cases. The list of studies conducted by the program since 1996 can be accessed at www.cps.ca/cpsp.

<table>
<thead>
<tr>
<th>Provinces/territories</th>
<th>Reporting rates (%)</th>
<th>Number of participants</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alberta (AB)</td>
<td>79</td>
<td>315</td>
</tr>
<tr>
<td>British Columbia (BC)</td>
<td>74</td>
<td>268</td>
</tr>
<tr>
<td>Manitoba (MB)</td>
<td>86</td>
<td>118</td>
</tr>
<tr>
<td>New Brunswick (NB)</td>
<td>78</td>
<td>29</td>
</tr>
<tr>
<td>Newfoundland and Labrador (NL)</td>
<td>76</td>
<td>52</td>
</tr>
<tr>
<td>Nova Scotia (NS)</td>
<td>89</td>
<td>96</td>
</tr>
<tr>
<td>Northwest Territories (NT)</td>
<td>100</td>
<td>2</td>
</tr>
<tr>
<td>Nunavut (NU)</td>
<td>100</td>
<td>2</td>
</tr>
<tr>
<td>Ontario (ON)</td>
<td>77</td>
<td>1,007</td>
</tr>
<tr>
<td>Prince Edward Island (PE)</td>
<td>100</td>
<td>7</td>
</tr>
<tr>
<td>Quebec (QC)</td>
<td>79</td>
<td>594</td>
</tr>
<tr>
<td>Saskatchewan (SK)</td>
<td>76</td>
<td>49</td>
</tr>
<tr>
<td>Yukon (YT)</td>
<td>100</td>
<td>1</td>
</tr>
<tr>
<td>Canada</td>
<td>79</td>
<td>2,540</td>
</tr>
</tbody>
</table>
Confidentiality is maintained by using only non-nominal patient information, such as the date of birth and sex of the child. This anonymous information is used to exclude duplicates and is sent to the original respondent to request case-specific information.

Once the detailed questionnaire is returned to the CPSP, it is forwarded to the investigator for analysis. If further information is required to confirm or exclude a case, the program manager contacts the respondent on behalf of the investigator.

Participants who do not reply every month receive reminders. In addition, information on the monthly compliance rates and the number of cases reported is mailed quarterly to all participants to keep them informed of progress. In 2011, the national reporting rate was 79% (Table 1) and the response rate for completion of detailed questionnaires, 85% (Table 2).

### Participant workload

The monthly reporting system is simple and the follow-up study questionnaires are easy to complete. As only non-nominal, non-identifiable data are collected through the CPSP, respondents do not hesitate to provide clinical information.

In 2011, the majority of participants (87%) had ‘nil’ cases to report. The importance of zero reporting must be re-emphasized. Table 3 illustrates the number of cases reported by respondents in 2011. As studies come and go, the workload shifts to different subspecialties. Through the years, studies with national collaborative networks have been very successful. The 2011 study with the most reports was severe iron-deficiency anemia in infants and young children.

The CPSP is extremely grateful that the majority of participants faithfully complete the detailed questionnaires subsequent to reporting cases. This demonstrates that they appreciate the enormous value of the scientific data collected and reinforces the Steering Committee’s insistence on short, precise and pertinent detailed questionnaires.

To thank paediatricians and paediatric subspecialists for their tremendous commitment and support, names of participants who completed the initial reporting forms for all months in 2011 and/or returned one or more detailed questionnaires were entered in draws for various prizes.

### Investigators’ corner

The CPSP provides investigators, through its timely, active surveillance system, an innovative means of obtaining non-nominal, national data on low-frequency diseases and conditions from over 2,500 participants. The program is committed to a high case ascertainment rate and, due to follow-up reminders to non-respondents, obtains a response rate of 85% on detailed questionnaires (Table 2). The CPSP offers an opportunity for international

---

### Table 2 – 2011 detailed questionnaire completion rates as of May 1, 2012

<table>
<thead>
<tr>
<th>Studies/conditions</th>
<th>Reported cases*</th>
<th>Pending</th>
<th>% Completion rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute flaccid paralysis</td>
<td>48</td>
<td>6</td>
<td>88</td>
</tr>
<tr>
<td>Adrenal suppression</td>
<td>34</td>
<td>11</td>
<td>68</td>
</tr>
<tr>
<td>Adverse drug reactions – serious and life-threatening</td>
<td>40</td>
<td>6</td>
<td>85</td>
</tr>
<tr>
<td>Conversion disorder in children and youth</td>
<td>35</td>
<td>15</td>
<td>57</td>
</tr>
<tr>
<td>Early-onset neonatal sepsis and meningitis</td>
<td>108</td>
<td>21</td>
<td>81</td>
</tr>
<tr>
<td>Langerhans cell histiocytosis</td>
<td>33</td>
<td>4</td>
<td>88</td>
</tr>
<tr>
<td>Neonatal hyperbilirubinemia – severe (2011-2013)</td>
<td>53</td>
<td>9</td>
<td>83</td>
</tr>
<tr>
<td>Paediatric myasthenia</td>
<td>22</td>
<td>0</td>
<td>100</td>
</tr>
<tr>
<td>Periodic fever syndromes</td>
<td>27</td>
<td>3</td>
<td>89</td>
</tr>
<tr>
<td>Persistent albuminuria in the paediatric population with type 2 diabetes mellitus</td>
<td>34</td>
<td>0</td>
<td>100</td>
</tr>
<tr>
<td>Respiratory syncytial virus (RSV) infections in paediatric transplant patients</td>
<td>15</td>
<td>1</td>
<td>93</td>
</tr>
<tr>
<td>Severe iron-deficiency anemia in infants and young children</td>
<td>115</td>
<td>12</td>
<td>89</td>
</tr>
<tr>
<td>Travel-related illnesses in paediatric travellers who visit friends and relatives abroad</td>
<td>9</td>
<td>0</td>
<td>100</td>
</tr>
<tr>
<td><strong>Total number of cases (all studies)</strong></td>
<td><strong>573</strong></td>
<td><strong>88</strong></td>
<td><strong>85</strong></td>
</tr>
</tbody>
</table>

* Excluding duplicate and excluded cases

---

### Table 3 – Number of cases reported by respondents in 2011

<table>
<thead>
<tr>
<th>Number of cases</th>
<th>% Respondents</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>87</td>
</tr>
<tr>
<td>&lt;5</td>
<td>13</td>
</tr>
<tr>
<td>5–10</td>
<td>0.9</td>
</tr>
<tr>
<td>&gt;10</td>
<td>0.1</td>
</tr>
</tbody>
</table>
Surveillance at Work

collaboration with other paediatric surveillance units worldwide and a chance to make a difference in the health and well-being of Canadian children and youth.

Individual researchers are encouraged to submit proposals for new studies that meet the Criteria for Inclusion, and follow the Format for Submission, available on the CPSP website at www.cps.ca/cpsp. The Steering Committee reviews submissions at its spring and fall meetings, giving preference to studies that have either strong scientific and public health importance or those that could not be undertaken any other way. Following the review, studies must receive ethical approval and have external funding arrangements in place before final acceptance to the program. Researchers interested in obtaining more information about the program are encouraged to visit the website or contact the manager of surveillance at cpsp@cps.ca.

One-time survey questions

The CPSP is also available to investigators as a cost-effective tool to survey participants on a one-time basis in order to identify the prevalence of a problem or to answer a specific question. Once approved by the CPSP Steering Committee, the one-time survey is sent to all participants with the monthly initial reporting form. Collected results are forwarded to the investigator for data analysis.

Results of the 2011 one-time survey questions are found on pages 38-44, and the list of surveys completed to date can be accessed at www.cps.ca/cpsp.

Glossary of terms for tables of cases in each study results
Reported: Reports of cases received
Duplicates: Cases reported by more than one participant
Excluded: Cases not meeting the case definition
Pending: Detailed reports not received or not yet confirmed
Confirmed: Cases verified as meeting the case definition
CPSP Principal Investigators

Surveillance studies in 2011

Dr. Shalini Desai
*Acute flaccid paralysis*

Dr. Ellen Goldbloom
*Adrenal suppression*

Margaret Zimmerman
*Adverse drug reactions – serious and life-threatening*

Dr. Christina Grant
*Conversion disorder in children and youth*

Dr. Michael Sgro
*Early-onset neonatal sepsis and meningitis and Neonatal hyperbilirubinemia – severe (2011–2013)*

Dr. Bruce Crooks
*Langerhans cell histiocytosis*

Dr. Hanna Kolski
*Paediatric myasthenia*

Dr. Paul Dancey
*Periodic fever syndromes*

Dr. Elizabeth Sellers
*Persistant albuminuria in the paediatric population with type 2 diabetes mellitus*

Dr. Joan Robinson
*Respiratory syncytial virus infections in paediatric transplant patients*

Dr. Patricia Parkin
*Severe iron-deficiency anemia in infants and young children*

Dr. Maryanne Crockett
*Travel-related illnesses in paediatric travellers who visit friends and relatives abroad*
Surveillance Studies in 2011

Acute flaccid paralysis
January 1996 to December 2013
S Desai, T Smith

Highlights 2011
• Vigilant surveillance of acute flaccid paralysis (AFP) is essential in light of ongoing transmission of wild poliovirus in countries around the world.
• Neurological investigations (MRI, EEG, etc.) occur in 91% of all AFP cases.
• Guillain-Barré syndrome (GBS) is the most frequent diagnosis for AFP in Canada.
• Canada's AFP surveillance continues to work towards World Health Organization (WHO) targets for AFP detection, stool specimen collection and follow-up for residual paralysis.

Background and objectives
The complete protocol can be accessed at www.cps.ca/cpsp.

Case definition
Acute onset of focal weakness or paralysis characterized as flaccid (reduced tone) without other obvious cause (e.g., trauma) in children less than 15 years of age. Transient weakness (e.g., postictal weakness) does not meet the case definition.

Results
There were 58 notifications of AFP through the CPSP to the Public Health Agency of Canada with onset in 2011, which included 35 confirmed cases. Approximately 51% of all reports came from the CPSP network and 49% from IMPACT. Five AFP reports were excluded because they did not meet the case definition: four based on age criteria and one based on diagnosis. The 35 confirmed cases represent a non-polio AFP detection rate of 0.62/100,000 in children less than 15 years of age (Table 2).

In 2011, AFP cases ranged in age from one week to 14 years (median 5 years, mean 5 years), and were fairly evenly distributed across age groups. A total of 51% of AFP cases were male and 49% were female.

Among the reported AFP cases in 2011, documentation of age-appropriate polio immunization was found to be incomplete: 15 cases (43%) had documented receipt, one case (3%) was recorded as “up-to-date” with no further information and the remaining 19 cases (54%) included no information on immunization. Vaccine uptake rates of inactivated poliovirus vaccine (IPV) in Canada are approximately 80% for four doses or more among 7 year olds.

Investigation for polio virus, other enteroviruses or Campylobacter
Virological investigation included testing of stool specimens for 14 cases (40%), cerebrospinal fluid (CSF) for 20 cases (57%) and throat swabs for 12 cases (34%). Where stool was collected, 86% had an adequate sample taken within 14 days from the onset of paralysis. In the remaining cases, stool collection was later, when the sensitivity of enterovirus isolation is lower. Overall, 34% (n=12) of cases had an adequate stool sample collected within 14 days of the onset of paralysis (Table 2). None of the samples collected in 2011 were positive for polioviruses. Testing was also conducted for Campylobacter in 15 cases (43%) and was not isolated in any of the samples.

Neurological investigations
In 2011, approximately 91% of cases underwent at least one type of neurological investigation (CSF examination, nerve conduction studies/electromyography, MRI/CT scan) with CSF exams and MRI/CT scans used most
Surveillance Studies in 2011

frequently in 77% and 80% of cases respectively. Of those cases that had a test, approximately 70% had abnormal CSF chemistry results, 89% had abnormal electromyography and/or nerve conduction studies and 68% had abnormal MRI or CT scans.

As observed in previous years, the majority of AFP cases (22, 63%) were diagnosed as GBS, three of which were Miller-Fisher variant. The remaining 13 cases were diagnosed as transverse myelitis (n=3), botulism (n=2) and other (n=8).

**Hospitalization and outcome**

All confirmed AFP cases reported in 2011 required hospitalization. Except in four cases with unknown length of stay, length of hospital stay ranged from one to 29 days (median 10 days, mean 12 days). Outcome at the time of the initial report was documented in 33 cases (94%): six (18%) fully recovered, 25 (76%) partially recovered with residual weakness or paralysis and two (6%) had not fully recovered. There were no deaths. Only 16 cases (46%) had clinical outcome reported at 60 days, including 12 cases who had fully recovered, two with partial recovery (i.e., some residual weakness or paralysis) and two had not recovered or outcomes were pending.

**Discussion**

The majority of cases of poliomyelitis are asymptomatic; a small percentage of cases, approximately 4–8%, may manifest as a nonspecific fever and sore throat. Approximately 1% of cases develop paralytic poliomyelitis. Symptoms of this form of polio include severe muscle pain and stiffness of the back and neck; rapid onset of asymmetric acute flaccid paralysis may occur. There is usually a fever present at the onset of illness and the paralysis depends on the location of nerve cell infection. If poliomyelitis is suspected in a patient, further consultation with a neurologist and infectious diseases consultant would be prudent.

Based on the current 2011 AFP case data, Canada failed to meet WHO quality assurance criteria for non-polio AFP incidence rate (1.0/100,000), stool sampling (80%) or 60 day follow up (80%). The recommended target for non-polio AFP incidence has only been met three times since AFP surveillance began in 1996 (1999, 2000 and 2009). The targets for stool testing and 60 day follow-up have never been met.

Canada’s consistently lower than expected AFP rates over the years could be a result of under-detection of cases, in combination with delayed reporting, or could be a true reflection of lower baseline levels for non-polio AFP in Canada. The low rates of stool sampling may be a result of diagnostic practices used in Canada. Given that most AFP cases are diagnosed as either GBS or transverse myelitis, physicians may favour neurological investigations where results are known quickly. With respect to 60 day follow-up, most AFP cases are not admitted to acute care hospitals for over 60 days, resulting in data gathering difficulties.

The Public Health Agency of Canada and the CPSP have undertaken a study to compare the AFP surveillance systems used by countries that are part of the International Network of Paediatric Surveillance Units. It is expected that the result of this study will help to target improvements to the AFP surveillance system in Canada. In addition, efforts will continue towards improving the data collection form, evaluating the functionality of the AFP surveillance systems and exploring ways of supplementing the AFP data system used in Canada.

<table>
<thead>
<tr>
<th>Year</th>
<th>Number of cases</th>
<th>Incidence rate</th>
<th>% with adequate stool sample*</th>
<th>% with 60 days follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td>1996</td>
<td>27</td>
<td>0.45</td>
<td>18.5</td>
<td>70.4</td>
</tr>
<tr>
<td>1997</td>
<td>35</td>
<td>0.59</td>
<td>28.6</td>
<td>45.7</td>
</tr>
<tr>
<td>1998</td>
<td>43</td>
<td>0.72</td>
<td>25.6</td>
<td>46.5</td>
</tr>
<tr>
<td>1999</td>
<td>60</td>
<td>1.01†</td>
<td>33.3</td>
<td>33.3</td>
</tr>
<tr>
<td>2000</td>
<td>64</td>
<td>1.09†</td>
<td>45.3</td>
<td>37.5</td>
</tr>
<tr>
<td>2001</td>
<td>52</td>
<td>0.89</td>
<td>36.5</td>
<td>38.5</td>
</tr>
<tr>
<td>2002</td>
<td>44</td>
<td>0.75</td>
<td>31.8</td>
<td>34.1</td>
</tr>
<tr>
<td>2003</td>
<td>44</td>
<td>0.76</td>
<td>34.1</td>
<td>22.7</td>
</tr>
<tr>
<td>2004</td>
<td>38</td>
<td>0.66</td>
<td>44.7</td>
<td>28.9</td>
</tr>
<tr>
<td>2005</td>
<td>53</td>
<td>0.93</td>
<td>26.4</td>
<td>32.1</td>
</tr>
<tr>
<td>2006</td>
<td>39</td>
<td>0.69</td>
<td>20.5</td>
<td>43.6</td>
</tr>
<tr>
<td>2007</td>
<td>50</td>
<td>0.89</td>
<td>42.0</td>
<td>46.0</td>
</tr>
<tr>
<td>2008</td>
<td>42</td>
<td>0.75</td>
<td>33.3</td>
<td>42.9</td>
</tr>
<tr>
<td>2009</td>
<td>59</td>
<td>1.05†</td>
<td>30.5</td>
<td>49.2</td>
</tr>
<tr>
<td>2010</td>
<td>46</td>
<td>0.82</td>
<td>34.8</td>
<td>54.3</td>
</tr>
<tr>
<td>2011</td>
<td>35</td>
<td>0.62</td>
<td>34.3</td>
<td>45.7</td>
</tr>
</tbody>
</table>

* Adequate stool sample refers to one stool sample taken within 14 days of paralysis onset
† WHO target met
Surveillance Studies in 2011

Global Polio Eradication Initiative (GPEI)
www.polioeradication.org
In 2011, there were 650 cases of wild poliovirus reported which represents a decrease of 48% from the 2010 global case count. In addition, India, one of four remaining endemic countries, reported only one case of polio and has now reported no new cases in over a year. However, the three other endemic countries (Afghanistan, Pakistan, Nigeria) continued to experience persistent transmission throughout 2011 along with Chad, Angola and the Democratic Republic of Congo. As a result of ongoing transmission, seven countries had new outbreaks of polio in 2011; most notably China after over 10 years without any wild poliovirus cases.

The Independent Monitoring Board, which monitors the progress of the GPEI, released a report in October 2011 warning that current funding gaps and program deficiencies were threatening the goal of stopping polio transmission in 2012. The WHO’s Executive Board subsequently declared polio eradication a “programmatic emergency for global public health” and planned to table this resolution at the 65th Session of the World Health Assembly in May, 2012.

Reference

Acknowledgements
The contribution of Kelly Mansfield is greatly appreciated.

1 Principal investigator
Shalini Desai, MD, FRCP, Centre for Immunization and Respiratory Infectious Diseases, Public Health Agency of Canada; shalini.desai@phac-aspc.gc.ca
**Adrenal suppression**

**April 2010 to March 2012**

A Ahmet¹, E Goldbloom¹, S Abish, S Benseler, E Cummings, H Huynh, A Mokashi, A-M Ugnat, W Watson

---

**Highlights 2011**

- In the second year of surveillance, 16 cases of symptomatic adrenal suppression (AS) were confirmed while 17 are still under review.
- Adrenal crisis, a condition with significant morbidity, was confirmed in one case.
- The most common presentations were growth failure and non-specific symptoms.
- The predominant type of glucocorticoid (GC) treatment in most of the cases reported was inhaled corticosteroids. Many were treated with more than one form of GC (e.g., inhaled and intranasal).
- There were no reported cases of AS for children being treated with intranasal GCs alone.

---

**Background and objectives**

The complete protocol can be accessed at www.cps.ca/cpsp.

**Case definition**

Report any new patient less than 18 years of age treated with any form of glucocorticoid therapy with evidence of adrenal suppression defined as:

1. Adrenal crisis, an acute critical illness out of proportion in severity to the current illness and manifested by any of the following:
   - Hypotension/shock
   - Decreased level of consciousness/lethargy
   - Unexplained hypoglycemia or hyponatremia
   - Seizure
   - Death

or

2. Symptomatic* adrenal insufficiency with supportive biochemical evidence

* Signs/symptoms can include anorexia, weakness, fatigue, lethargy, fever, gastrointestinal symptoms (nausea, vomiting, constipation, diarrhea, abdominal pain), morning headache, hypoglycemia, myalgia, arthralgia, psychiatric symptoms and growth failure.

**Exclusion criteria**

Adrenal insufficiency unrelated to GC therapy, including adrenocorticotropic hormone (ACTH) deficiency due to hypothalamic or pituitary gland abnormalities, and primary adrenal disorders, such as:

- Congenital adrenal hyperplasia
- Autoimmune adrenalitis or polyglandular syndromes
- Adrenal hypoplasia congenita
- ACTH resistance syndromes
- Metabolic disorders (adrenoleukodystrophy, peroxisome biogenesis disorders, cholesterol metabolism, mitochondrial disorders)
- Infectious disorders (sepsis, tuberculosis, fungal infections, viral infections)
- Infiltrative/destructive causes (hemorrhage, amyloidosis, sarcoidosis, metastases)
- Drugs inhibiting steroid biosynthesis (e.g., ketoconazole, etomidate, suramin, aminoglutethimide, metyrapone)

**Results**

**Demographics**

In the second year of surveillance, 16 cases of symptomatic AS have been confirmed to date. Ten (63%) were male. The mean age at diagnosis of AS was 7.3 years (range 2.5–15.9). All were Caucasian. The underlying conditions requiring GC treatment included: asthma alone (13 cases, 81%); asthma, atopy and subglottic stenosis (one case, 6%); arthritis (one case, 6%); and vasculitis (one case, 6%). Eight (50%) cases were from Quebec, six (38%) were from Ontario and two (13%) were

---

**TABLE 1 – AS cases in 2011**

<table>
<thead>
<tr>
<th>Reported</th>
<th>Duplicates</th>
<th>Excluded</th>
<th>Pending</th>
<th>Confirmed</th>
</tr>
</thead>
<tbody>
<tr>
<td>62</td>
<td>3</td>
<td>26</td>
<td>17</td>
<td>16</td>
</tr>
</tbody>
</table>
Surveillance Studies in 2011

from western provinces. The confirmed cases presented to a physician’s office or clinic (13 cases, 81%), on the inpatient unit (one case, 6%), and to the emergency department (two cases, 13%). One patient who presented to the emergency department was transferred to the intensive care unit.

Glucocorticoid therapy
Fourteen children received inhaled corticosteroids, as solo therapy (n=6) or in combination with oral GC (n=1), intranasal GC (n=2), intranasal and short course oral GC (n=4) or oral and topical (n=1). Two children received primarily systemic GCs: a combination of intravenous and oral GCs (n=1) and oral only (n=1). The specific types, doses and treatment durations of GCs were variable and were not consistently reported. The most commonly reported inhaled corticosteroid was fluticasone, usually in doses of 500 mcg/day for months to years.

Presentation
Of the 16 confirmed cases of symptomatic AS, the most common presentations were growth failure and non-specific symptoms (e.g., fatigue, nausea, myalgia). One case (6%) had adrenal crisis. The presenting symptoms and signs of the remaining cases are described in Table 2.

Physical activity
The underlying condition requiring GC therapy caused a decrease in physical activity in five (31%) children. The GC therapy caused a decrease in physical activity in one (6%) child. Five (31%) children experienced a weight gain on GC therapy.

Outcome and management
After confirmation of AS, 15 (94%) children were treated with GC replacement and 12 (75%) were seen by or referred to an endocrinologist. One (6%) child was hospitalized for three days (adrenal crisis), two of which were in the intensive care unit. The other 15 children (94%) were managed as outpatients.

Conclusion
The minimal estimated incidence of symptomatic AS to date is approximately 20 cases per year in the Canadian paediatric population. The majority of the reported cases involved inhaled corticosteroids. Physicians must be aware of the potential side effects of asthma therapy and frequently revisit GC doses to ensure that patients are being treated with the lowest effective dose to reduce the risk of AS.

A large proportion of patients presented with growth failure or non-specific symptoms. This underlines the importance of close monitoring of children’s growth and potential symptoms associated with AS. The lack of consistent, specific signs and symptoms of AS means that many cases may not be recognized without proactive screening.

Over the past 21 months, this CPSP study has provided an ideal format for data collection to estimate the frequency and morbidity of paediatric AS in Canada. It has also been an effective tool in raising awareness about this condition and contributing to the recognition of children at risk of AS.

Publications and presentations
Adverse drug reactions – serious and life-threatening
January 2004 to December 2013
M Zimmerman

Highlights 2011
• The study confirmed 29 suspected paediatric adverse reaction (AR) cases.
• Product groups most commonly associated with suspected adverse reactions were psychoanaleptics, antibacterial agents, antiepileptics and immunosuppressants.
• The quality of clinical information gathered via the CPSP is considered to be good to excellent as per the quality grading scale used by the World Health Organization (WHO).

Background and objectives
The complete protocol can be accessed at www.cps.ca/cpsp.

Case definition
Report serious and life-threatening adverse reactions* in an infant or child up to the age of 18 years, associated with the use of prescription, non-prescription, biological (immunoglobulin) products, complementary medicines (including herals) and radiopharmaceutical products.

* Noxious and unintended severe response to a health product, which occurs at any dose and results in emergency observation, hospitalization, persistent or significant disability or death.

Exclusions
Do not report reactions to medical devices, blood products (platelets, red cells and single-donor plasma), vaccines, poisonings or self-administered overdoses.

Results
From January 1 to December 31, 2011, 44 cases of suspected serious adverse drug reactions (ADRs) were reported and 29 cases were confirmed as meeting the case definition. In comparison, 42, 67, 68 and 45 reports were received via the CPSP in 2010, 2009, 2008 and 2007 respectively. The quality of clinical information gathered via the CPSP is considered to be good to excellent as per the quality grading scale used by WHO.

Of the 29 confirmed cases, 15 were male and 14 were female. The age range was from one month to 17 years. Table 2 provides a comparison of the age distribution of confirmed AR reports from 2007 to 2011.

All 29 cases were classified as serious (more than one reason for seriousness was reported in 15 cases). Table 3 shows a comparison of the reasons for seriousness received in the past five years. Information regarding patient outcome was provided for 24 of the 29 confirmed cases as follows: recovered (n=18), not yet recovered (n=4), recovered with sequelae (n=1), death (n=1).

Suspected health products
Table 4 lists the health products described in the 29 AR reports, sorted by number of reports received per each individual product. In 23 reports, a single product was suspected of the causing the reaction(s). Two
Surveillance Studies in 2011

suspected products were reported in six cases. The classes of health products most frequently suspected of causing adverse reaction(s) were psychoanaeptics (n=7; four cases with psychostimulant agents used for the treatment of attention deficit and hyperactivity disorders and three cases with antidepressants) followed by antibacterial agents (n= 6), antiepileptics (n=4) and immunosuppressants (n=3). The most frequently involved health product classes have varied somewhat each year; however, the top four classes have generally included these classifications. Additional information regarding the reported confirmed AR reports is accessible online at www.cps.ca/cpsp.

Conclusion

The classes of health products most frequently suspected of causing adverse reaction(s) in 2011 were psychoanaeptics, followed by antibacterial agents, antiepileptics and immunosuppressants. All of these classes of health products are used frequently in the treatment of paediatric patients.

The ongoing sharing of adverse reaction reports through the CPSP is key to enhancing the safety of health products for children.

Publications and presentations


Grenier D, Zimmerman M. ¿Una vigilancia estricta puede mejorar el reporte de reacciones adversas a medicamentos? XII Congreso Nacional de Pediatría, CoNaPeMe, Guadalajara, May 2011. (Oral presentation)

1 Principal investigator
Margaret Zimmerman, BSc, Patient Safety Section, Marketed Health Products Directorate, Health Canada, Bldg 7, AL 0701C, Tunney’s Pasture, Ottawa ON K1A 0K9; tel.: 613-957-2806; fax: 613-948-7996; margaret.zimmerman@hc-sc.gc.ca

### TABLE 3 – Annual comparison of reasons for seriousness of confirmed cases

<table>
<thead>
<tr>
<th></th>
<th>2011 (n=29)</th>
<th>2010 (n=32)</th>
<th>2009 (n=51)</th>
<th>2008 (n=40)</th>
<th>2007 (n=45)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Death</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>3</td>
<td>0</td>
</tr>
<tr>
<td>Life-threatening</td>
<td>11</td>
<td>6</td>
<td>14</td>
<td>12</td>
<td>9</td>
</tr>
<tr>
<td>Hospitalization</td>
<td>18</td>
<td>19</td>
<td>28</td>
<td>18</td>
<td>18</td>
</tr>
<tr>
<td>Disability</td>
<td>4</td>
<td>2</td>
<td>3</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Medically important condition*</td>
<td>15</td>
<td>17</td>
<td>21</td>
<td>12</td>
<td>11</td>
</tr>
</tbody>
</table>

* A medically important reaction is defined as one that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the patient or may require intervention to prevent one of these other outcomes from occurring.

### TABLE 4 – Suspected health products reported in AR reports (n=29) in 2011

<table>
<thead>
<tr>
<th>Suspected health product</th>
<th># Time reported (n=36)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infliximab</td>
<td>3 (n=3)</td>
</tr>
<tr>
<td>Atomoxetine, carbamazepine, methylphenidate hydrochloride (extended release)*, ibuprofen, drospirenone/ethinyl estradiol†</td>
<td>2 each (n=10)</td>
</tr>
<tr>
<td>Ceftriaxone, cefuroxime, citalopram, diphenhydramine, doxycycline, fentanyl, flecainide, indomethacin, ifosfamide,isoniazid, ketamine, lamotrigine, linezolid, meropenem, methotrexate, midazolam, risperidone, romiflostimon, succinylcholine, sulfasalazine, trazodone, valproic acid, venlafaxine</td>
<td>1 each (n=23)</td>
</tr>
</tbody>
</table>

* All reported as Concerta®.
† Combination products containing two active ingredients (Yaz®, Yasmin®)
Conversion disorder in children and youth

September 2011 to August 2013

C Grant1, C Krasnik1, J Cairney, A Chapman, M Connolly, S Findlay, O Jamouille, A Kam, E Lipman, R MacNay, B Meaney

Highlights 2011
• The majority of confirmed conversion disorder (CD) cases are female which is consistent with the literature.
• The average age of confirmed cases is 13.7 years with a range of 9–16 years.

Background and objectives
The complete protocol can be accessed at www.cps.ca/cpsp.

Case definition
Report any new patient less than 18 years of age with suspected or diagnosed conversion disorder* defined as the persistent appearance of symptoms/signs that affect the patient’s:
• Voluntary motor function (e.g., weakness, abnormal gait or movements, difficulty with swallowing or loss of speech) and/or
• Sensory function (e.g., loss or diminished sensation of touch, sight, or hearing) and/or
• Non-epileptic seizures (“pseudoseizures” or “psychogenic seizures”) and suggest a neurological or medical disease/condition and
• May be accompanied by psychological factors at presentation
• Cause significant distress and/or impairment in daily activities, such as self-care, school, play, peer and family relationships and/or activities and
• Cannot be adequately explained by a medical condition, substance abuse, or other mental disorder according to the clinical judgment of the treating physician after a comprehensive physical exam and appropriate investigations
• Show no evidence that they have been intentionally produced

* If the diagnosis is uncertain or awaiting confirmation, the case should still be reported.

Exclusion criteria
Patients who have predominantly or exclusively symptoms that are secondary to substance abuse; intentionally produced; secondary to pain disorder, somatization disorder or fatigue; due exclusively to another psychiatric disorder, such as depression, psychosis or tic disorder diagnosed by a child psychiatrist

Results
In the first four months of surveillance, 46 CD cases were reported, meeting the expected study target of a total of 200 cases over two years. With only 11 cases confirmed to date, it is premature to report on detailed results. In the literature, CD is reported more frequently in females. So far, 91% of confirmed cases are females with an average age of 13.7 years (range 9–16). The presenting complaints vary widely, including altered sensation, loss of consciousness, visual changes and dizziness. The majority of confirmed cases required hospitalization with an average length of stay of six days (range 2–19). Analysis of the 33 pending cases will provide a better description of clinical features at presentation, associated features, such as comorbid psychiatric or medical illness and family history of psychiatric illness, the pattern and severity of illness, associated psychosocial features and the current management of children and youth with CD.

| TABLE 1 – CD cases from September 1 to December 31, 2011 |
|---------------------------------|----------|----------|--------|--------|---------|
| Reported                        | Duplicate| Excluded | Pending| Confirmed|
| 46                              | 1        | 1        | 33     | 11      |

1 Principal investigators
Christina Grant, MD, FRCP(C), Division of Adolescent Medicine, Department of Paediatrics, McMaster University, 3G48-1200 Main St W, Hamilton ON L8N 3Z5; tel.: 905-521-2100, ext. 75644; fax: 905-308-7548; chgrant@mcmaster.ca
Catherine Krasnik, MD, PhD, FRCP(C), Clinical Fellow, Psychiatry and Behavioural Neurosciences, McMaster University, 3G48-1200 Main St W, Hamilton ON L8N 3Z5; tel.: 905-572-1838; fax: 905-308-7548; krasnice@mcmaster.ca
Early-onset neonatal sepsis and meningitis
Neonates less than seven days of age
January 2011 to December 2012
M Sgro\textsuperscript{1}, DM Campbell, S Lee, K Sankaran, D Tran, M Yudin

\textbf{Highlights 2011}
- In the first year of surveillance, 61 cases of early-onset neonatal sepsis and meningitis (NSM) were confirmed.
- Antibiotic prophylaxis during labour was given to 33\% of mothers.
- Group B \textit{Streptococcus} and \textit{E. coli} accounted for the vast majority of cases.
- There appear to be very few cases of sepsis caused by other types of bacteria.

\textbf{Background and objectives}
The complete protocol can be accessed at www.cps.ca/cps.

\textbf{Case definition}
Report any neonate less than seven days of age presenting with one of the following:
- Positive blood culture\textsuperscript{*}
and/or
- Positive cerebrospinal fluid (CSF) culture\textsuperscript{*} from a lumbar puncture (LP)

Neonates with possible nosocomial infections should also be reported.
\* Culture growth includes bacterial or fungal pathogens

\textbf{Exclusion criteria}
- Neonates who are asymptomatic with positive culture, such as coagulase-negative \textit{Staphylococcus}, Diphtheroids, \textit{Corynebacterium} \textit{spp.}, \textit{Bacillus} \textit{spp.}, \textit{Propionibacterium} \textit{spp.}, \textit{Aerococcus} \textit{spp.}, \textit{Micrococcus} \textit{spp.}.
- Positive CSF from a drain, reservoir, shunt or intracranial surgical procedure

\textbf{Results}
In the first year of surveillance, 109 cases of early-onset neonatal sepsis and meningitis were reported. Of these, 61 were confirmed, seven were excluded for not meeting the case definition, one was a duplicate and 40 are pending review. The 61 confirmed cases were predominantly from Ontario (n=19) and Quebec (n=18), while six other provinces each reported less than seven cases (BC, AB, MB, NB, NS, NL).

All included infants were born between 24 and 41 weeks gestation, with a mean gestational age of 35 weeks and a mean birth weight of 2,697 g (range 568–4,290). The male to female ratio is 1.1:1 (32 males, 29 females). Maternal group B \textit{Streptococcus} status was positive in 15 cases (25\%), negative in 26 cases (43\%) and unknown in 20 cases (33\%); however, 20 mothers (33\%) received antibiotic prophylaxis.

During the surveillance, bacteria were confirmed primarily from blood cultures (n=56); however, positive cerebral spinal fluid cultures were also reported in five cases. Initial data analysis suggests that group B \textit{Streptococcus} (49\%) and \textit{E. coli} (28\%) were the most commonly reported positive bacterial cultures. There appear to be very few cases of positive cultures caused by other bacterial organisms.
Understanding the neonatal infection pattern in Canada is of paramount importance with regards to both maternal intrapartum antibiotic guidelines and neonatal management.

Publications and presentations
Sgro M, Yudin MH, Lee S, Sankaran K, Tran D, Campbell DM. Early-onset neonatal sepsis: it is not only group B streptococcus. *Paediatr Child Health* 2011; 16(5): 269


Sgro M. Neonatal sepsis and the changing patterns of infection. Paediatric Update, Canadian Paediatric Society Annual Conference, Quebec City, June 2011. (Oral presentation)

---

1 Principal investigator
Michael Sgro, MD, FRCPC, University of Toronto, Department of Paediatrics, St. Michael’s Hospital, Room 014, 15th floor, Cardinal Carter Wing, 30 Bond St, Toronto ON M5B 1W8; tel.: 416-864-6060, ext. 6560; fax: 416-864-6073; sgrom@smh.ca
Surveillance Studies in 2011

Langerhans cell histiocytosis

July 2009 to June 2012

B Crooks†, D Dix, L Parker, S Weitzman

Highlights 2011

- The study confirmed 18 new Langerhans cell histiocytosis (LCH) cases in 2011 and a total of 40 confirmed cases to date.
- The average age at diagnosis is 4 years 5 months (range: birth to 16 years, 4 months).
- Patients often experience delay to diagnosis of up to 60 weeks and see multiple health care professionals.

Background and objectives

The complete protocol can be accessed at www.cps.ca/cpsp.

Case definition

Report any new patient presenting from birth to the 18th birthday with:

- Clinical LCH features that may include unexplained bone pain and soft tissue swelling, diabetes insipidus and hypothalamic-pituitary dysfunction, proptosis, recurrent otitis or otorrhoea, maculopapular rash or seborrhoeic dermatitis or napkin dermatitis resistant to treatment, interstitial pneumonitis or sclerosing cholangitis and
- Either a) or b)
  a) Biopsy-proven LCH, with lesional cells containing:
     - Birbeck granules demonstrated on electron microscopy and/or
     - CD1a positive cells and/or
     - Langerin-positive cells and/or
     - S100 positive cells with characteristic H&E histopathology
  b) Lytic bony lesions or pituitary/hypothalamic lesions characteristic of LCH without biopsy where:
     - Risks of biopsy are considered too hazardous due to site of lesion
     - Lesion has shown characteristic spontaneous regression

Results

For this study, national surveillance of LCH is conducted using three parallel methods: the CPSP, the C17 network of paediatric haematology/oncology centres and the other allied specialty physicians (orthopaedics, neurosurgery, ENT, dermatology, ophthalmology, endocrinology and pathology). In 2011, 24 cases of LCH were reported to the CPSP. Of these, 18 were confirmed. Only two cases were reported via the alternate pathway and not through the CPSP. Neither is confirmed.

Of the 18 confirmed cases, 14 were males and four were females. The main ethnicity reported was Caucasian and others included South Asian, Native American and Middle Eastern. There were six cases from Ontario and Quebec, respectively. The remaining cases were in four provinces (BC, AB, MB, NS). The mean age at diagnosis was 4 years 5 months (range: birth to 16 years, 4 months). Presenting features were varied. There were 10 cases of single-system bony disease: the orbit (n=4), the skull (n=3), the long bones (n=2) and the vertebra (n=1). Three cases presented with polyuria/polydipsia, two of whom had multisystem disease, and one had skull-based disease. Multisystem disease occurred in three cases involving young infants. Three patients presented with solitary skin disease. Those with skin disease had extended times from onset to diagnosis (12 to 60 weeks).

Treatment was by curettage alone (n=3), observation (n=3), non-steroidal anti-inflammatory drugs (NSAIDs) (n=1) and steroid and vinblastine (n=9). Two further cases failed initial treatment with steroid/vinblastine and

<table>
<thead>
<tr>
<th>TABLE 1 – LCH cases in 2011</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reported</td>
</tr>
<tr>
<td>24</td>
</tr>
</tbody>
</table>

CPSP 2011 RESULTS
received cytarabine and cladribine, with or without 6-mercaptopurine and/or dexamethasone. No clinical trials for LCH therapy were open during 2011. All cases survived.

Currently, 40 LCH cases have been confirmed during the first 2.5 years of this study. Case acquisition will close in July 2012. Only four cases have been reported via the alternate pathways. Additional efforts will be made to collect further cases and outstanding data. Most cases involve bony disease. The time from onset to diagnosis appears to be long, and patients see multiple health care professionals.

Publications and presentations

---

1 Principal investigator
Bruce Crooks, MB, ChB, Paediatric Haematology/Oncology, Dalhousie University, IWK Health Centre, 5850-5980 University Ave, Halifax NS B3K 6R8; tel.: 902-470-8048; fax: 902-470-7216; bruce.crooks@iwk.nshealth.ca
Surveillance Studies in 2011

Infants 60 days or less
March 2011 to February 2013
M Sgro¹, T Barozzino, DM Campbell, T Longpre, M Ofner, V Shah

Highlights 2011
• In the first 10 months of surveillance, 22 cases of severe neonatal hyperbilirubinemia were confirmed. The mean reported peak bilirubin level was 461 μmol/litre.
• ABO incompatibility was the most common cause of severe hyperbilirubinemia followed by G6PD deficiency and other antibodies.

Background and objectives
The complete protocol can be accessed at www.cps.ca/cpsp.

Case definition
Report any infants 60 days of age or less with unconjugated hyperbilirubinemia and who have had:
• Peak serum total bilirubin > 425 μmol/L or
• Neonatal exchange transfusion

Exclusion criteria
Infants who have had exchange transfusion for well-documented Rh isoimmunization disease or who were born at less than 35 weeks gestational age.

Results
In the first 10 months of surveillance, 57 cases of severe neonatal hyperbilirubinemia were reported in infants 60 days of age or less. Of these, 22 were confirmed, six were excluded for not meeting the case definition and 29 are under review. There have been no duplicate reports thus far.

As expected from the inclusion criteria, the mean gestational age was 38 weeks (range 36–41) with a birth weight of 3,262 g (range 2,569–3,770). Of the confirmed cases, most were reported from Ontario (n=8) and Quebec (n=6). The remaining cases were from British Columbia, Alberta, Saskatchewan and Nunavut. The female to male ratio is 1.2:1 and all infants were breast-fed.

The cause of severe hyperbilirubinemia was identified in about half (12/22) of the confirmed cases. ABO incompatibility (n=8) was the most common cause followed by G6PD deficiency (n=2) and other antibodies (n=2). The mean reported peak bilirubin level was 461 μmol/litre (range 301–604), compared to the 468 μmol/litre (range 137–773) found in the 2002–2004 CPSP study. Phototherapy was required in 20 confirmed cases, of which four received intravenous immunoglobulin and two needed exchange transfusion. Two infants were reported to have received no treatment. Data from this study will allow for comparison with two previous CPSP studies, namely severe neonatal hyperbilirubinemia (2002–2004) and kernicterus (2007–2009). The goal of this specific surveillance study is to look at rates of severe hyperbilirubinemia/kernicterus pre-and post-introduction of the 2007 Canadian Paediatric Society’s position statement, Guidelines for detection, management and prevention of hyperbilirubinemia in term and late preterm newborn infants (35 or more weeks’ gestation), and to comment on the effectiveness of the guidelines.

¹ Principal investigator
Michael Sgro, MD, FRCP, University of Toronto, Department of Paediatrics, Li Ka Shing Knowledge Institute, St. Michael’s Hospital, Room 014, 15th floor, Cardinal Carter Wing, 30 Bond St, Toronto ON M5B 1W8; tel.: 416-864-6060, ext. 6560; fax: 416-864-6073; sgrom@smh.ca
Paediatric myasthenia

January 2010 to December 2011 – Final report

H Kolski¹, J Vajsar¹

Highlights

• In two years of national surveillance, 57 cases of paediatric myasthenia (PM) were confirmed.
• A high index of suspicion is required to diagnose PM; a significant percentage of patients (33% with generalized symptoms and 56% with exclusively ocular symptoms) demonstrated normal titres of acetylcholine receptor antibodies.
• There appears to be a significant overlap with other autoimmune disorders, particularly thyroid diseases.
• PM is a treatable disease; readily available treatments include pyridostigmine, prednisone and intravenous immunoglobulin (IVIG).
• Early recognition and management of PM helps to avoid unnecessary testing, prevents the progression of symptoms and lessens morbidity and mortality.

Background and objectives

The complete protocol can be accessed at www.cps.ca/cpsp.

Case definition

Report any child less than 18 years of age with at least one of the following clinical features:
• Fluctuating ptosis (unilateral or bilateral) and/or
• Fluctuating extraocular muscle weakness (unilateral or bilateral) and/or
• History of skeletal muscle weakness or fatigue

and any of the following supportive tests:
• Tensilon™ test (edrophonium) (or other acetylcholinesterase inhibitor) demonstrating reversal of weakness
• Elevated acetylcholine receptor or MuSK (muscle specific kinase) antibody levels
• Abnormal nerve conduction studies (demonstrating defect in neuromuscular junction transmission) or single fiber EMG

Exclusion criteria

• Underlying primary muscle disease
• Underlying metabolic disease
• Transient neonatal myasthenia

Results

In two years of national surveillance, 57 confirmed cases of PM were reported from Alberta, Manitoba, Ontario, Quebec and Newfoundland. Three cases were excluded: two for insufficient information and one for wrong diagnosis. The completion rate of the detailed questionnaires was 100%. There were 34 generalized and 18 purely ocular reports of PM in children. There were 14 incident cases in 2010 and six in 2011: 13 generalized and seven ocular. Overall, the median age of onset was 10 years (range birth to 17) for the generalized form compared to three and a half years (range 18 months to 11 years) for the ocular subtype. The ratio of male to female was 1:1.1 in the generalized group and 1:2.6 in the younger ocular group. Positive acetylcholine receptor titres were found in 22/33 (67%) of generalized cases and 8/18 (44%) ocular patients. A high index of suspicion is therefore required to diagnose PM; a significant percentage of patients did not have elevated screening acetylcholine receptor antibodies. In these cases, further precise diagnostic evaluation was required. There were five reports of congenital myasthenic syndrome.

TABLE 1 – PM cases from January 1, 2010 to December 31, 2011

<table>
<thead>
<tr>
<th>Year</th>
<th>Reported</th>
<th>Duplicate</th>
<th>Excluded</th>
<th>Pending</th>
<th>Confirmed</th>
</tr>
</thead>
<tbody>
<tr>
<td>2010</td>
<td>39</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>37</td>
</tr>
<tr>
<td>2011</td>
<td>25</td>
<td>2</td>
<td>3</td>
<td>0</td>
<td>20</td>
</tr>
<tr>
<td>Total</td>
<td>64</td>
<td>4</td>
<td>3</td>
<td>0</td>
<td>57</td>
</tr>
</tbody>
</table>
Surveillance Studies in 2011

Initial treatments
For the 34 patients presenting with generalized symptoms, early treatment course information was available for 33 patients. All were started on pyridostigmine; improvement was noted in 100%. Eighteen patients received steroids; improvement was cited in 17/18 (94%). Of those tried on IVIG, improvement was reported in 17/21 (81%).

For the 18 patients with exclusively ocular presentations, 17 had prescribed medications listed. Improvement occurred in 15/17 (88%) patients started on pyridostigmine. All 10 patients started on prednisone improved. IVIG was reported to help one out of two patients.

Associated conditions
There appears to be a high association of PM with thyroid disorders. Two antibody positive patients were concurrently diagnosed with Grave’s disease. Another patient had elevated antimicrosomal antibodies. Four patients had a family history of Hashimoto’s/thyroid disease.

Conclusion
This study represents the largest descriptive series of paediatric myasthenia in North America. It provides valuable information about clinical characteristics and raises awareness regarding the diagnosis. A high index of suspicion is required even in patients with normal titres of acetylcholine receptor antibodies. PM is a treatable disease. Children generally respond promptly to readily available treatments including pyridostigmine, prednisone and IVIG. Early recognition and management of PM helps to avoid unnecessary testing, prevents the progression of symptoms and lessens morbidity and mortality.

Publications and presentations

Kolski H. Paediatric myasthenia: first year of active national surveillance. 46th Annual Congress of the Canadian Neurological Sciences Federation, Vancouver, June 2011. (Oral presentation)

1 Principal investigators (representing the Canadian Pediatric Neuromuscular Group)
Hanna Kolski, MD, FCRPC, Stollery Children’s Hospital, University of Alberta, Department of Pediatrics, 4-588 Edmonton Clinic Health Academy, 11405 – 87 Avenue, Edmonton AB T6G 1C9; tel.: 780-248-5569; fax: 1-888-353-1163; hanna.kolski@albertahealthservices.ca

Jiri Vajsar, MD, FRCPC, The Hospital for Sick Children, University of Toronto, 555 University Ave, Toronto ON M5G 1X8; tel.: 416-813-5668; fax: 416-813-6334; jiri.vajsar@sickkids.ca
Periodic fever syndromes

September 2011 to August 2014

P Dancey1, S Benseler, M Gattorno, A Junker, R Laxer, P Miettunen, L Turner

Highlights 2011

• Periodic fever, aphthous stomatitis, pharyngitis and adenitis (PFAPA) was the most commonly reported periodic fever syndrome (PFS) during the initial four months of surveillance.
• Familial Mediterranean fever and undefined PFS were also reported.
• Most patients have seen multiple physicians before receiving a diagnosis.

Background and objectives

The complete protocol can be accessed at www.cps.ca/cpsp.

Case definition

Report any patient less than 18 years of age presenting with a newly diagnosed periodic fever syndrome (autoinflammatory syndrome) meeting the criteria outlined below.

Inclusion criteria

Patients must have one of the following diagnoses (see protocol for specific details outlined in the appendix and for characteristic features in the table; the protocol can be accessed at www.cps.ca/cpsp):
• Familial Mediterranean fever (FMF)
• Tumor necrosis factor receptor-associated periodic syndrome (TRAPS)
• Hyperimmunoglobulinemia D syndrome (HIDS)
• Cryopyrin-associated periodic syndromes (CAPS), including familial cold autoinflammatory syndrome (FCAS), Muckle-Wells syndrome (MWS), and neonatal-onset multisystem inflammatory disease (NOMID)
• Periodic fever, aphthous stomatitis, pharyngitis and adenitis (PFAPA)
• Periodic fever syndrome – undefined

Exclusion criteria

• Detailed clinical assessment and investigations compatible with infections, malignancy, or the classical inflammatory or autoimmune rheumatic diseases (e.g., systemic lupus erythematosus, systemic juvenile idiopathic arthritis, inflammatory bowel disease)
• Febrile attacks with regular periodicity and low neutrophil counts, suggestive of cyclic neutropenia

Results

During the initial four months of surveillance, 25 cases of PFS were reported. Of the 11 confirmed cases, eight were PFAPA, two were FMF and one was undefined PFS. The average age at diagnosis was four years old (range 1–7). No cases of TRAPS, CAPS or HIDS have been reported to date. This may reflect the rarity of these conditions, but also the requirement for genetic testing confirmation causing a delay in the final reporting. Most cases have been evaluated by more than two physicians before receiving a diagnosis (range 1–4). The majority of reporting physicians are general paediatricians, in addition to rheumatologists and geneticists. Further progress through the course of this three-year surveillance study should clarify the full spectrum and incidence of PFS cases in Canada.

Table 1 – PFS cases from September 1 to December 31, 2011

<table>
<thead>
<tr>
<th>Reported</th>
<th>Duplicate</th>
<th>Excluded</th>
<th>Pending</th>
<th>Confirmed</th>
</tr>
</thead>
<tbody>
<tr>
<td>25</td>
<td>1</td>
<td>0</td>
<td>13</td>
<td>11</td>
</tr>
</tbody>
</table>

1 Principal investigator
Paul Dancey, MD, FRCP, Janeway Children’s Hospital, Memorial University, St. John’s NL A1B 3V6; tel.: 709-777-4766; fax: 709-777-4343; paul.dancey@easternhealth.ca
**Persistent albuminuria in the paediatric population with type 2 diabetes mellitus**

**April 2010 to March 2012**

S Hadjiyannakis¹, E Sellers¹, S Amed, A Dart, H Dean, R Dyck, J Hamilton, V Langlois, C Panagiotopoulos, A-M Ugnat

---

**Highlights 2011**

• Persistent albuminuria was confirmed in 16 children less than 18 years of age with type 2 diabetes mellitus (T2DM).
• Children of Aboriginal heritage appear to be disproportionally affected.
• A family history of diabetes-related renal disease and exposure to pre-gestational or gestational diabetes is frequently found.

**Background and objectives**

The complete protocol can be accessed at www.cps.ca/cpsp.

**Case definition**

Report any patient up to 18 years of age with type 2 diabetes mellitus and **persistent** microalbuminuria or macroalbuminuria, defined as 2/3 positive samples at least one month apart over a 3–6 month period.

**Canadian Diabetes Association definition of diabetes:**

• Fasting plasma glucose (FPG) \( \geq 7.0 \text{ mmol/L} \) * or
• Random plasma glucose \( \geq 11.1 \text{ mmol/L} \) * or
• Two-hour plasma glucose \( \geq 11.1 \text{ mmol/L} \) after a standard oral glucose tolerance test

* Requires a second, confirmatory test if child is asymptomatic

**Diagnosis of T2DM will be based on the following clinical features:**

• Obesity (body mass index >95th percentile for age and gender)
• Family history of T2DM in a first or second degree relative(s)
• Belonging to a high-risk ethnic group (e.g., Aboriginal, African, Hispanic, South-Asian)
• A history of exposure to diabetes in utero (diagnosed before or during pregnancy)
• Evidence of insulin resistance: acanthosis nigricans, polycystic ovarian syndrome, hypertension, dyslipidemia
• Absence of diabetes-associated autoantibodies when available

---

**Results**

Of the 16 confirmed cases during 2011, 12 (75%) were female and 14 (88%) were in children of self-declared Aboriginal heritage (13 First Nations, one Métis). A regional variation was noted with 75% of cases from Manitoba, 19% from northwestern Ontario and 6% from Nova Scotia.

---

**TABLE 1 – Definition of albuminuria*  
24-hour urine collection for albumin**

<table>
<thead>
<tr>
<th>Albuminuria</th>
<th>Urine albumin to creatinine ratio (ACR)†</th>
<th>24-hour urine collection for albumin</th>
</tr>
</thead>
</table>
| Microalbuminuria  | 2.0–20.0 mg/mmol (male)  
                    | 2.8–28.0 mg/mmol (female)            | 30–300mg/day (male or female)       |
| Macroalbuminuria  | >20.0 mg/mmol (male)  
                    | >28.0 mg/mmol (female)              | >300 mg/day (male or female)        |

* Persistent albuminuria defined as 2/3 positive samples over a 3–6 month period, samples must be at least one month apart
† Confirmation with either first-morning urine sample or overnight urine collection

---

**TABLE 2 – Persistent albuminuria in children with T2DM cases in 2011**

<table>
<thead>
<tr>
<th>Reported</th>
<th>Duplicate</th>
<th>Excluded</th>
<th>Pending</th>
<th>Confirmed</th>
</tr>
</thead>
<tbody>
<tr>
<td>21</td>
<td>0</td>
<td>0</td>
<td>5</td>
<td>16</td>
</tr>
</tbody>
</table>

---

30

**CPSP 2011 RESULTS**
The mean age at diagnosis of albuminuria was 13.6 years (range 9.8–17.7) (male 16.1; female 11.7 years). Associated co-morbidities were common, with dyslipidemia the most frequently reported in 9/16 cases (56%), hypertension in 8/16 (50%), and non-alcoholic liver disease in 3/16 (19%). Frequent findings included exposure to pre-gestational diabetes (6/16, 38%), exposure to gestational diabetes (3/16, 19%) and a family history of diabetes-related renal disease (9/16, 56%).

Preliminary results indicate that persistent non-orthostatic albuminuria in youth with T2DM does occur in Canada and that children of Aboriginal heritage appear to be disproportionally affected. National surveillance for the prevalence of albuminuria in children with T2DM is necessary to define the spectrum and extent of the problem. This is important for predicting the burden of illness and for planning screening and intervention programs. This data will be useful for paediatricians, community physicians, community health professionals, policy makers and program planners. Furthermore, the data will provide a baseline prevalence estimate for future comparison. Identification of the population of children with T2DM and persistent albuminuria will facilitate research to understand the etiology and prevention of this significant complication.

Publications and presentations

---

1 Principal investigators
Stasia Hadjiyannakis, MD, FRCPC, Section of Paediatric Endocrinology, Children’s Hospital of Eastern Ontario, Ottawa ON K1H 8L1; tel.: 613-737-7600; fax: 613-738-4236; shadjiyannakis@cheo.on.ca

Elizabeth Sellers, MD, FRCPC, Section of Paediatric Endocrinology and Metabolism, Winnipeg Children’s Hospital, Winnipeg MB R3E 0Z2; tel.: 204-787-4351; fax: 204-787-1655; esellers@exchange.hsc.mb.ca
Respiratory syncytial virus infections in paediatric transplant patients
September 2010 to August 2013
JL Robinson1, U Allen, I MacLusky

Highlights 2011
• The incidence of severe respiratory syncytial virus (RSV) infections in paediatric solid organ or haematopoietic stem cell transplants appears to be low.

Background and objectives
The complete protocol can be accessed at www.cps.ca/cpsp.

Case definition
Report all inpatients and outpatients less than 18 years of age who have:
• Laboratory-confirmed RSV infection
and
• Received solid organ transplantation or haematopoietic stem cell transplantation within the two previous years

Results
Ten cases of paediatric transplant patients with RSV infections were confirmed in 2011. Of these, four cases were nosocomial: two in liver recipients (11 days and 6 months post-transplant respectively), one in a kidney recipient (63 days post-transplant) and one in an allogeneic haematopoietic stem cell recipient (16 days post-transplant). None of these four cases required ventilation.

Three cases were community-acquired infections that were not severe. One case occurred 10 months post-transplant in an allogeneic haematopoietic stem cell recipient who was not admitted to hospital. Two cases occurred in kidney recipients: one at 55 days post-transplant was admitted to hospital but not ventilated; the second at 20 months post-transplant was not admitted.

The final three cases survived severe RSV infections and required ventilation for: three days (lung recipient, 33 days post-transplant), six days (liver recipient, five months post-transplant) and 21 days (allogeneic haematopoietic stem cell recipient, 22 days post-transplant).

The incidence of severe RSV infections in paediatric solid organ or haematopoietic stem cell transplant patients appears to be low. As RSV prophylaxis is available, gathering data on the incidence and morbidity associated with RSV infection in Canadian transplant recipients is of utmost importance to establish potential costs and benefits of palivizumab in this population.

Publications and presentations
Robinson JL, Grenier D. What happens when you mix a transplant with respiratory syncytial virus? Paediatr Child Health 2011; 16(1): 12

1 Principal investigator
Joan L. Robinson, MD, FRCPC, Stollery Children’s Hospital, Division of Pediatric infectious Diseases, Department of Paediatrics, University of Alberta, Edmonton AB T6G 2J3; tel.: 780-407-1680; fax: 780-407-7136; jr3@ualberta.ca

| TABLE 1 – RSV infections in paediatric transplant patients cases in 2011 |
|----------------|----------------|---------|-------|------|
| Reported       | Duplicate     | Excluded| Pending| Confirmed |
| 17             | 0             | 5       | 2     | 10     |
Severe iron-deficiency anemia in infants and young children
October 2009 to September 2011 – Final report
P Parkin¹, S Zlotkin¹, M Belletrutti, M Carcao, J Grabowski, A-M Ugnat, S Wong

Highlights
• Severe iron-deficiency anemia (IDA) continues to occur in Canada, with 195 confirmed cases in two years.
• Dietary factors such as prolonged bottle-feeding, excessive cow’s milk and/or inadequate iron-enriched food intake were involved.
• Asian and Aboriginal populations were over-represented in the study sample, accounting for 36% and 12% of the confirmed cases, respectively.
• Significant morbidity is associated with severe IDA, including developmental delay, heart failure, cerebral thrombosis and health care utilization.

Background and objectives
The complete protocol can be accessed at www.cps.ca/cpsp.

Case definition
Report all otherwise healthy infants and young children from six to 36 months of age with severe iron-deficiency anemia defined as: Hemoglobin <80 g/L and low mean corpuscular volume (MCV; below normal for age) plus one or more of the following:
• Low ferritin
• Low iron
• High transferrin receptor
• High free-erythrocyte protoporphyrin
• Correction of anemia with iron therapy

Exclusion criteria
• Chronic disease known to be associated with anemia
• Diseases associated with malabsorption
• Conditions associated with blood loss, such as trauma, surgery and frequent bloodletting
• Known congenital hemoglobinopathy
• Known disorders of clotting
• Blood loss due to acute or chronic disease causing gastrointestinal bleeding

Results
Throughout the two years of surveillance, 340 cases of severe IDA were reported in infants and young children. Sixty-five cases were excluded for the following reasons: not meeting inclusion criteria for anemia (n=19), age (n=14), confirmatory biochemical laboratory test such as ferritin (n=4), date of diagnosis (n=13) and presence of a disease known to be associated with anemia (n=2); inability to locate chart/patient by respondent (n=13); reported by lab with no details of case known (n=1); and child excluded by physician (n=1). Two children were excluded for more than one reason. A total of 195 cases were confirmed. The reporting rate for completion of the detailed questionnaire was 84%. The estimated incidence of severe IDA in infants aged 12 to 36 months is 12/100,000 (Statistics Canada, 2006 Census), which may be an underestimate.

The mean age of patients was 18 months (range 6–36). Where information was provided, almost half of the cases’ mothers were Caucasian (82/182, 45%), 65 (36%) were Asian, 21 (12%) were Aboriginal and 14 (8%) were other

---

TABLE 1 – Severe IDA cases from October 1, 2009 to September 30, 2011

<table>
<thead>
<tr>
<th>Year</th>
<th>Reported</th>
<th>Duplicate</th>
<th>Excluded</th>
<th>Pending</th>
<th>Confirmed</th>
</tr>
</thead>
<tbody>
<tr>
<td>2009*</td>
<td>38</td>
<td>0</td>
<td>14</td>
<td>6</td>
<td>18</td>
</tr>
<tr>
<td>2010</td>
<td>152</td>
<td>8</td>
<td>23</td>
<td>24</td>
<td>97</td>
</tr>
<tr>
<td>2011†</td>
<td>150</td>
<td>14</td>
<td>28</td>
<td>28</td>
<td>80</td>
</tr>
<tr>
<td>Total</td>
<td>340</td>
<td>22</td>
<td>65</td>
<td>58</td>
<td>195</td>
</tr>
</tbody>
</table>

* October 1, 2008 to December 31, 2009
† January 1, 2011 to September 30, 2011
Surveillance Studies in 2011

ethnicities. This suggests an over-representation of the overall Asian population, which is 12% of the Canadian population (Statistics Canada, 2006 Census). The Aboriginal population is also over-represented in this study, as Aboriginals represent 4% of the Canadian population (Statistics Canada, 2006 Census). However, in this survey Aboriginals might be under-reported, as very few paediatricians are working in remote northern communities.

The median hemoglobin level was 55 g/L (interquartile range [IQR] 45–67), median MCV was 51.9 fl (IQR 49.1–55.0) and median serum ferritin was 3.8 μg/L (IQR 2–8).

Of the 195 infants, 154 (79%) were receiving cow’s milk at diagnosis of IDA; their mean daily consumption was 1.1 L (38 oz), with a range of 200 mL to 2.4 L (7–81 oz). Inadequate intake of iron-enriched foods was reported in 89 infants (46%). Current or previous breast-feeding was found in 124 infants (64%). Of those children over 12 months of age, 111/140 (79%) reported using the bottle during the day and 60% reported using the bottle in bed. Presenting signs that prompted the physician to request laboratory investigations included pallor (n=126), poor weight gain (n=20), developmental delay (n=13), poor energy (n=45), fever (n=29), irritability (n=37), infectious illness (n=58), underweight (n=15), edema (n=11), pica (n=13) and poor feeding (n=10). Almost one-quarter (23%) had complications, particularly developmental delay (n=33), evidence of heart failure (n=9) and cerebral thrombosis (n=2). In all cases, the attending physician prescribed oral iron supplementation and provided dietary counselling. Hospital admission was needed in 83 cases (43%); of these, 25 required a blood transfusion and 42 had a consultation with a paediatric hematologist. Transfusions for children with IDA are usually reserved for severe anemia with complications. The median reported hemoglobin level in children requiring a blood transfusion in this study population was 36 g/L (IQR 28–46).

Conclusion
The results from these 24 months of surveillance demonstrate that severe IDA is being reported in Canadian infants and young children and is associated with significant morbidity. Dietary factors likely played an etiologic role in most confirmed cases, including inadequate intake of iron-enriched foods and high consumption of cow’s milk. Primary prevention through nutrition counselling of young children may lead to reductions in severe IDA. Secondary prevention through screening young children, especially those with high risk factors, for early stages of iron deficiency before the onset of anemia should be an area for future research.

Publications and presentations

Wong S. The landscape of severe iron-deficiency anemia in Canada. Paediatric Update Session. Canadian Paediatric Society Annual Conference, Quebec City, June 2011. (Oral presentation)

1 Principal investigators
Patricia Parkin, MD, FRCPC, Division of Paediatric Medicine and the Paediatric Outcomes Research Team (PORT), The Hospital for Sick Children and the Research Institute, University of Toronto, Toronto ON M5G 2X9; tel.: 416-813-6933; fax: 416-813-5663; patricia.parkin@sickkids.ca

Stanley Zlotkin, MD, PhD, FRCP(C), Department of Paediatrics, Division of Gastroenterology, Hepatology and Nutrition, and the Research Institute, The Hospital for Sick Children and the Research Institute, University of Toronto, Toronto ON M5G 2X9; tel.: 416-813-6171; fax: 416-813-4972; stanley.zlotkin@sickkids.ca
Travel-related illnesses in paediatric travellers who visit friends and relatives abroad
March 2009 to February 2011 – Final report
M Crockett1, L Ford-Jones, D Grondin, C Hui, J Keystone, S Kuhn

Highlights
• During the two years of surveillance, 91 confirmed cases of significant travel-related illnesses (TRIs) occurred among paediatric travellers who visited friends and relatives abroad (VFRs).
• Enteric fever ("typhoid fever") and malaria were the most common types of travel-related illnesses.
• A majority of confirmed cases did not obtain pre-travel advice.
• Almost three-quarters of the cases required hospitalization with an average length of stay of 12 days.

Background and objectives
The complete protocol can be accessed at www.cps.ca/cpsp.

Case definition
A travel-related illness is acquired while travelling abroad and symptoms may develop during travel or following the child’s return to Canada. A VFR traveller may be a foreign-born child or the Canadian-born child of foreign-born parents who is travelling to a country of origin to visit friends and relatives. The diagnosis is made on clinical and/or laboratory criteria.

Report all children living in Canada less than 18 years of age who acquire significant travel-related illnesses while travelling abroad as VFR travellers.

Exclusion criteria
• Children who develop travel-related illnesses but did not travel to visit friends and relatives
• Children who acquire non-specific mild travellers’ diarrhea and respiratory infections, not requiring hospitalization

Results
During the two years of surveillance, 129 cases were reported. The study confirmed 91 cases of TRIs in paediatric VFRs (Table 1). Among these, 42 (46%) were reported from Ontario, 14 (15%) from British Columbia, 12 (13%) from Quebec, 11 (12%) from Alberta, 10 (11%) from Manitoba and the remaining cases were from Saskatchewan and Prince Edward Island. The regions of travel and the types of TRIs acquired by paediatric VFRs are summarized in Tables 2 and 3 respectively.

The majority (81%) presented with fever. Diarrhea (42%), vomiting (18%), abdominal pain (16%), cough (16%), headache (12%), rash (9%) and jaundice (9%) were also common symptoms. The majority of patients with TRIs were initially seen in the emergency department (64%) as compared to the physician’s office or clinic (36%). The interval of time between the beginning of travel and the onset of symptoms ranged from a few days to several months with an average of 62 days due to the long duration of travel for some children. The interval of time between the onset of symptoms and the physician visit varied depending on the type of travel illness, as did the time between the onset of symptoms and diagnosis.

The average duration of travel was approximately 7 ½ weeks. Almost all VFR children travelled to urban areas with 49% travelling exclusively to urban areas and 42% to both rural and urban areas. Only 9% travelled
Surveillance Studies in 2011

exclusively to rural locations. The majority of confirmed cases (79%), whose type of accommodation was known, stayed in family homes, only 19% of which were documented to have air conditioning and/or insect screens. Other risk factors included ingestion of food from street vendors (18%), unsafe water (19%), unpasteurized dairy products (5%) and uncooked or unpeeled fruits and vegetables (22%).

Among the 91 confirmed cases, 24 obtained pre-travel advice and 45 did not; in 22 cases it was unknown whether any advice was received. Of those who received pre-travel advice (n=24), eight obtained it from a travel clinic physician, five from a paediatrician, four from a family doctor and seven respondents did not specify from whom they received advice.

Of those who obtained pre-travel advice, 11 patients were not compliant with the advice given regarding vaccines (n=2) or antimalarials (n=9). In eight cases it was unknown whether the advice was given correctly and not followed or was inappropriate. Four cases did not receive recommended pre-travel vaccines and/or antimalarial medications for their destinations according to recognized travel medicine guidelines. One primary vaccine failure was reported in a case with enteric fever; however, the effectiveness of typhoid vaccines is known to be only about 70%.

More than 70% of patients with TRIs required hospitalization (n=65) with an average length of stay of 12 days (mean=12, median=6). Of note, two patients required admissions of approximately three months duration. Three patients were critically ill at presentation: one presented with hypotension due to malaria and two presented with septic shock secondary to *Salmonella* species bacteremia. Four patients required admission to intensive care units. Four children were left with significant sequelae and there was one death due to septic shock.

**Conclusion**

There were 91 confirmed cases of significant TRIs among paediatric VFRs during the surveillance period from 2009–2011. These numbers likely under-represent the burden of TRIs among paediatric VFRs because the case definition excludes mild respiratory and gastrointestinal illnesses that do not require hospitalization.

The results of this surveillance study are consistent with information regarding TRIs among adults, given that paediatric VFRs generally travelled for at least several weeks, stayed in family homes, and ingested unsafe food and water. The majority (82%) of TRIs in this study sample occurred in children who travelled to Asia. Only one-quarter of the paediatric VFRs sought travel advice and, among those who did, several were not compliant with pre-travel recommendations and some received advice that did not follow standard travel medicine guidelines.

In this study, the majority of paediatric VFRs required hospitalization for their TRIs with an average length of stay of 12 days (mean=12, median=6), while two patients required admissions of approximately three months duration. This demonstrates that in addition to the significant morbidity experienced by paediatric VFRs in Canada, there are also significant associated costs to the health care system. Furthermore, the majority of the TRIs were potentially preventable if appropriate pre-travel advice had been obtained and followed. This study highlights the need to develop education and advocacy strategies to ensure that pediatric VFR travellers are able to access and comply with travel health advice in order to minimize their risk of acquiring travel-related illnesses. In particular, further research is needed to evaluate the barriers and facilitators to accessing and adhering to pre-travel services and recommendations for pediatric VFRs.

---

**TABLE 2 – Region of travel associated with TRIs**

<table>
<thead>
<tr>
<th>Region</th>
<th>Cases</th>
</tr>
</thead>
<tbody>
<tr>
<td>Asia</td>
<td>56</td>
</tr>
<tr>
<td>Africa</td>
<td>20</td>
</tr>
<tr>
<td>Central/South America</td>
<td>10</td>
</tr>
<tr>
<td>Middle East</td>
<td>5</td>
</tr>
<tr>
<td>Europe</td>
<td>1</td>
</tr>
</tbody>
</table>

* Some travellers developed TRIs following travel to more than one country.

**TABLE 3 – Types of TRIs acquired by paediatric VFRs**

<table>
<thead>
<tr>
<th>Type of Illness</th>
<th>Cases</th>
</tr>
</thead>
<tbody>
<tr>
<td>Enteric fever (suspected, confirmed)</td>
<td>36 (3, 33)</td>
</tr>
<tr>
<td>Malaria</td>
<td>17</td>
</tr>
<tr>
<td>Severe diarrheal illness</td>
<td>12</td>
</tr>
<tr>
<td>Hepatitis A</td>
<td>11</td>
</tr>
<tr>
<td>Parasitic infections</td>
<td>9</td>
</tr>
<tr>
<td>Symptomatic TB disease</td>
<td>5</td>
</tr>
<tr>
<td>Dengue</td>
<td>3</td>
</tr>
<tr>
<td>Respiratory disease (including H1N1)</td>
<td>3</td>
</tr>
<tr>
<td>Non-typhoidal <em>Salmonella</em> bacteremia</td>
<td>2</td>
</tr>
<tr>
<td>Measles</td>
<td>1</td>
</tr>
<tr>
<td>Brucellosis</td>
<td>1</td>
</tr>
<tr>
<td>UTI (multi-drug resistant organism)</td>
<td>1</td>
</tr>
</tbody>
</table>
Surveillance Studies in 2011

Publications and presentations


Crockett M. Travel-related illnesses in Canadian children. Canadian Paediatric Society Annual Conference, Vancouver, June 2010. (Poster presentation)


1 Principal investigator
Maryanne Crockett, MD, FRCPC, Department of Pediatrics and Child Health, Section of Pediatric Infectious Diseases, University of Manitoba, Winnipeg MB R3E 0J9; tel.: 204-789-3891; fax: 204-789-3926; crockett@cc.umanitoba.ca
Survey Questions

Accidental or intentional methadone exposure in children and young infants

October 2011

L Lewington¹, A Ornstein¹, SM Marcus, C Shaffer, A Vulliamy

Methadone is a synthetic opioid agonist widely used in methadone maintenance treatment (MMT) programs for people with opioid dependency, and less commonly used as analgesia for palliative care and chronic pain. It is dispensed as a brightly colored solution in a juice-like dilutant that must be refrigerated. Methadone presence in the home may precipitate accidental ingestion by a child mistaking the suspension for juice, or intentional exposure by a caregiver giving it to a child as a sedative. Sadly, ingestion of only 0.5 mg/kg of methadone can be lethal for a child.

A one-time CPSP survey was done to evaluate and raise awareness of accidental and intentional paediatric methadone exposure, and to capture the number of observed cases in Canada in a 12-month period.

The survey response rate was 25% (642/2,559). Of these, 27 (4%) respondents reported caring for at least one child with suspected or confirmed methadone exposure within the preceding 12 months; 78% identified one or two cases, 15% identified three or four cases and 7% identified between five and 10 cases. Perceived clinical outcomes are presented in Table 1. Only 15 of the 27 respondents who had seen a case indicated that a child welfare authority was notified. Of note, the same case may have been reported by more than one respondent.

Forty percent of respondents were unaware that methadone might be intentionally given to a child by a caregiver as a sedative and 27% were unaware that even a small dose can be potentially lethal in children. Only 45% knew the importance of counselling caregivers about safe storage of methadone in the home.

The results of this survey confirm that methadone ingestion in children is rare but can be lethal. Although less than 5% of all respondents had cared for methadone-exposed children, of those who had, 22% cared for multiple children (3–10 cases). This suggests that exposure may not be so very rare. The survey confirmed that paediatricians need more education about the risks and consequences of child methadone exposure as less than half of the respondents were aware that methadone may be intentionally given to a child as a sedative. Methadone exposure may be an under-recognized form of child maltreatment as just over half of the respondents who had seen a case indicated that a report to a child welfare authority was made. A targeted surveillance program would aid in further defining this issue in Canada.

<table>
<thead>
<tr>
<th>Perceived clinical outcomes</th>
<th>Frequency (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Not serious</td>
<td>11 (41)</td>
</tr>
<tr>
<td>Serious</td>
<td></td>
</tr>
<tr>
<td>- Hospitalization</td>
<td>15 (46)</td>
</tr>
<tr>
<td>- ICU admission</td>
<td>8 (30)</td>
</tr>
<tr>
<td>- Death</td>
<td>5 (19)</td>
</tr>
<tr>
<td>Data not reported</td>
<td>1 (4)</td>
</tr>
</tbody>
</table>

¹ Principal investigators
Laura Lewington, MD, paediatric resident, IWK Health Centre, Halifax NS B3K 6R8; tel.: 902-880-8457; laura.lewington@dal.ca
Amy Ornstein, MD, FRCP, Medical Director, Child Protection Team, IWK Health Centre, Halifax NS B3K 6R8; tel.: 902-470-8222; fax: 902-470-7761; amy.ornstein@iwk.nshealth.ca
A one-time survey was mailed to all 2,573 CPSP participants to assess the attitudes of Canadian allergists and paediatricians (non-allergists) towards non-controversial and controversial issues related to food allergy and food-induced anaphylaxis. Since accessibility to allergy specialists is variable across Canada and usually limited outside urban areas, paediatricians are playing a major role in the care of patients with allergic diseases. However, attitudes of allergists and non-allergists may differ for both non-controversial and controversial issues. The survey aimed to identify knowledge gaps that need to be bridged through appropriate educational programs. There were 533 CPSP responses, 25 from allergists and 508 from paediatricians (response rate 21%). Through parallel surveillance, 89 additional allergists were recruited from their medical association, the Canadian Society of Allergy and Clinical Immunology (CSACI). Overall, 114 allergists answered the survey.

Non-controversial issues
According to the 2010 Canadian consensus guidelines on the management of anaphylaxis in the primary care setting, the preferred route of epinephrine administration is intra-muscular (IM). In addition, although not mentioned in the consensus guideline, most experts now agree that for those with egg allergy, MMR immunization does not need to be given in a hospital setting as long as the immunization provider has an emergency kit containing epinephrine and is familiar with its use.

The survey revealed that 93% of allergists believe IM is the preferred route of epinephrine administration, versus 71% of paediatricians. Among allergists, less than 3% prefer the subcutaneous route. A smaller proportion of allergists compared to paediatricians require MMR immunization in a hospital facility in children with egg allergy (4% versus 12%).

Controversial issues
The appropriate age of introduction of allergenic foods remains controversial. The 2008 American Academy of Pediatrics’ revised position statement stipulated that there was no convincing evidence to support delaying the introduction of solid foods beyond the age of 4–6 months, including allergenic foods like egg white, in order to prevent food allergies. Also, there are no guidelines regarding the optimal timing for epinephrine administration during an allergic reaction, but it is clear that a delay in initiating therapy may result in increased morbidity and mortality in cases progressing to anaphylaxis. Hence, we queried physicians on these issues to assess their actual recommendations.

The survey revealed that allergists were less likely than paediatricians to recommend delayed introduction of egg white to children with and without a family history of atopy (with family history: 43% versus 61%; without family history: 22% versus 50%). When managing food-induced anaphylaxis, respondents tend to administer epinephrine to patients with allergic reactions involving generalized or systemic symptoms. Yet, more than 25% would not give epinephrine even when the patient has breathing difficulties or symptoms consistent with hypotension.

Conclusion
For non-controversial issues, a greater proportion of allergists adhere to current guidelines or literature recommendations. Surprisingly, 25% of respondents, regardless of their subspecialty, would not administer epinephrine for severe anaphylaxis, a situation in which it is clearly indicated. Future education programs need to address these gaps to avoid unnecessary restriction of MMR immunization and ensure prompt delivery of epinephrine when there is a concern that the allergic reaction may progress to anaphylaxis. These recommendations should be continuously updated to reflect advances in care. Finally, more research is required to determine best practices regarding appropriate age of introduction of allergenic foods.
Survey Questions

CPSP resource use
April 2011
A Quartaro

The CPSP provides supplemental resources to participants that include:
• A monthly educational tool on adverse drug reaction topics entitled ADR Tip of the Month
• Quarterly updates that summarize reported cases by region
• Biannual educational articles on study topics

A one-time survey was conducted to assess the use of the supplementary resources mailed to CPSP participants. Questions touched on were how frequently they read the supplemental CPSP resources, how helpful they found the material to be and how they disseminated the resources. The survey also asked for feedback on how the CPSP could make the resources more relevant to paediatric practice.

All 2,559 participants were sent the survey; the response rate was 27% (688/2,559). Results reaffirmed the importance of CPSP supplemental resources for program participants. Of the respondents, 65% (444/688) stated that they always read the ADR Tip of the Month; another 23% (158/688) read it sometimes. More than three-quarters (80%) of respondents said they read the quarterly updates and educational resources sometimes or always.

Interestingly, 82% of respondents found the ADR tips to be either very helpful (40%) or fairly helpful (42%). Certain groups of subspecialists did not find the tips to be particularly relevant to their practice. Respondents who shared the ADR information did so by posting to notice boards, circulating the hard copy to colleagues, presenting to students, discussing with colleagues and sharing with parents.

When asked about quarterly reports, 77% of participants responded that they always or sometimes read this resource; 63% felt this resource was either very or fairly helpful.

Educational resources are sent to participants twice per year, the latest having been sent five months prior to the survey being distributed. Respondents rated this resource as being fairly helpful (44%) and very helpful (28%).

The results of this survey confirm the high value that CPSP participants place on supplemental resources and the usefulness of ADR tips to provide paediatricians with timely information relevant to practice.

1 Principal investigator
Alison Quartaro, Canadian Paediatric Surveillance Program
Complications associated with energy drinks

March 2011

A Boutin¹, J Harvey¹, D Taddeo¹, J-Y Frappier

A one-time survey was conducted among all 2,510 CPSP participants to assess their screening practices regarding the use of energy drinks among children and youth. The survey also collected data on related complications encountered in the past 12 months and the reasons for the use of energy drinks mentioned by patients.

The survey response rate was 30%. Among the 741 respondents, 64% were general paediatricians, 35% were subspecialists and 1% did not specify their status.

Almost half of the respondents (46%) said they do not screen for the use of energy drinks: 57% were subspecialists and 41% were general paediatricians. Only 4% of respondents said they always screen for energy drink consumption while just under half (49%) screen occasionally. One percent did not answer.

Sixty-seven respondents (9%) reported they encountered patients with caffeine-related complications in the last 12 months: 52% were general paediatricians and 47% were subspecialists, including emergency medicine specialists (n=8), cardiologists (n=6) and adolescent medicine specialists (n=5). Fifty of these 67 respondents encountered less than five children and youth with complications. Fifteen percent of those who screen for energy drink use reported having seen patients with complications compared to only 2% of those who do not screen. Eighty-eight percent of those reporting complications were physicians who screen for the use of energy drinks. The types of reported complications are shown in Table 1.

<table>
<thead>
<tr>
<th>Complications</th>
<th>Frequency (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nervousness</td>
<td>35 (52)</td>
</tr>
<tr>
<td>Restlessness</td>
<td>34 (51)</td>
</tr>
<tr>
<td>Tachycardia</td>
<td>33 (49)</td>
</tr>
<tr>
<td>Palpitations</td>
<td>29 (43)</td>
</tr>
<tr>
<td>Insomnia</td>
<td>28 (42)</td>
</tr>
<tr>
<td>Headaches</td>
<td>20 (30)</td>
</tr>
<tr>
<td>Nausea</td>
<td>16 (24)</td>
</tr>
<tr>
<td>Arrhythmia</td>
<td>11 (16)</td>
</tr>
<tr>
<td>Hypertension</td>
<td>10 (15)</td>
</tr>
<tr>
<td>Vomiting</td>
<td>4 (6)</td>
</tr>
<tr>
<td>Vertigo</td>
<td>4 (6)</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>2 (3)</td>
</tr>
<tr>
<td>Seizures</td>
<td>1 (1.5)</td>
</tr>
<tr>
<td>Euphoria</td>
<td>1 (1.5)</td>
</tr>
<tr>
<td>Hallucinations</td>
<td>1 (1.5)</td>
</tr>
<tr>
<td>Death</td>
<td>1 (1.5)</td>
</tr>
<tr>
<td>Others</td>
<td>9 (13)</td>
</tr>
</tbody>
</table>

Thirteen out of 43 respondents (30%) who answered the question regarding the amount of energy drinks consumed at a time (during a short period) reported having seen children and youth who were drinking three or more cans/containers. Seventeen out of 37 respondents (46%) who answered the question regarding the amount consumed per day reported having seen children and youth who were drinking three or more cans/containers.

Among the physicians who reported complications (n=67), 28% reported that children and youth who presented with complications associated with energy drinks had also consumed alcohol and 26% reported the use of other drugs (psychostimulants 30%, cannabis 20%, amphetamine 10%). The majority of these respondents (78%) had seen the children and youth in an office setting.

The reasons physicians gathered from children and youth for the use of energy drinks are shown in Table 2.

<table>
<thead>
<tr>
<th>Reasons</th>
<th>Frequency (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Increase alertness</td>
<td>46 (72)</td>
</tr>
<tr>
<td>Peer pressure</td>
<td>25 (39)</td>
</tr>
<tr>
<td>Sport performance</td>
<td>16 (25)</td>
</tr>
<tr>
<td>Increase attention</td>
<td>7 (11)</td>
</tr>
<tr>
<td>Exam performance</td>
<td>6 (9)</td>
</tr>
<tr>
<td>Decrease alcohol effect</td>
<td>5 (8)</td>
</tr>
<tr>
<td>Weight loss</td>
<td>3 (5)</td>
</tr>
<tr>
<td>Others*</td>
<td>21 (33)</td>
</tr>
</tbody>
</table>

* Energy, pleasure, preference, social reasons

This one-time survey has some limitations, such as low response rate, assumed causal relationship of complications to energy drink use and, to a lesser extent, incomplete data submissions. However, the results show that 96% of respondents do not, or only occasionally, screen for energy drink use. Those who screen are finding possible complications associated with the use or abuse of energy drinks.
these drinks. Indeed, the results reveal potentially serious complications reported by 9% of respondents, mainly from those who screened.

Hopefully, this survey will increase awareness of potential health hazards associated with the use of energy drinks and the importance of screening, especially when confronted with certain symptoms.

Survey results also support initiatives to ensure that energy drinks no longer be labelled as natural health products, but rather managed as food, requiring the display of nutritional, ingredients and caffeine information. A maximum caffeine level for these products should also be set.

1 Principal investigators
Ariane Boutin, medical student, CHU Sainte-Justine, 3175, chemin de la Côte-Sainte-Catherine, Montréal QC H3T 1C5; arianeboutin@gmail.com
Johanne Harvey, MD, MPH, Adolescent Health Clinic, CSSS de Chicoutimi, 305 rue St-Vallier, Chicoutimi QC G7H 7X2; tel.: 418-541-1059; fax: 418-541-1157; harvey.johanne@sympatico.ca
Danielle Taddeo, MD, FRCPC, Department of Paediatrics, Adolescent Medicine Division, CHU Sainte-Justine, 3175, chemin de la Côte-Sainte-Catherine, Montréal QC H3T 1C5; tel.: 514-345-4722; fax: 514-345-4778; danielle.taddeo@ssss.gouv.qc.ca
An outbreak of necrotizing enterocolitis (NEC) in premature infants in the United States associated with the consumption of SimplyThick®, a thickening product, occurred in May 2011. Designed in partnership with the Public Health Agency of Canada, a one-time survey was sent to all CPSP participants to measure whether clinicians recommend the use of a thickening product for infants younger than one year and to document if Canadian cases of NEC were seen in the previous six months.

The survey response rate was 28% (741/2,660). Seventeen percent of respondents indicated having seen an infant hospitalized with NEC in the previous six months. Of those respondents, 77% had seen less than five cases, 12% reported five to 10 cases, and 9% reported more than 10 cases. Of note, 2% did not specify the number of cases seen.

Results showed that almost one-third (30%) of respondents have recommended the use of a thickening product for infants younger than one year. There was no question in the survey asking if the infant was premature or full term. Two cases of NEC in infants after the use of SimplyThick® were reported. One case, a premature infant (gestational age 27 4/7 weeks) who presented with NEC at 33 5/7 weeks, is deceased. The other case was alive and still in hospital at the time of the survey. Demographic information, including gestational age and age at presentation, was not available.

For a one-time survey, without reminders, a 28% response rate is in keeping with what is found in the literature. Clinicians would recall NEC cases as these are very sick infants requiring intensive care. Through a well-established surveillance network, public health authorities were able to rapidly collect information on an emerging issue.

1 Principal investigator
Rachel McCormick, Epidemiologist, Outbreak Management Division, Public Health Agency of Canada; tel.: 519-826-2991; fax: 519-826-2984
Survey Questions

Sudden unexplained death in children with epilepsy

August 2011

EJ Donner

Mortality rates in children with epilepsy exceed those of the general population. While many deaths may be explained by the underlying cause of seizures or co-morbid conditions, a proportion of deaths in children with epilepsy remain unexplained. The phenomenon of sudden unexpected death in epilepsy (SUDEP) refers to the death of a person with epilepsy that is sudden, unexpected and unexplained. Autopsy does not reveal a cause of death. SUDEP deaths may be witnessed or unwitnessed and may occur with or without evidence of a recent seizure.

The incidence of SUDEP in adults is estimated to be 1 death per 1,000 people with epilepsy per year, with rates approaching 1 per 100 person years in individuals with medically refractory seizures. The incidence of SUDEP in children has not been explored adequately; the limited literature suggests lower rates than in adults, ranging from 0.2 to 0.4 per 1,000 person years. These incidence rates are generally believed to be an underestimate, as it is widely acknowledged that poor awareness of SUDEP among health care practitioners and people with epilepsy results in low case ascertainment.

The CPSP conducted a one-time survey to determine whether a gap in knowledge of SUDEP exists among Canadian paediatricians and inform strategies for a prospective study of SUDEP among Canadian children. The survey was circulated to all CPSP participants and the response rate was 34% (866/2,570). Of the respondents, 78% (674/866) reported that they had cared for children with epilepsy in the preceding 24 months. Among these paediatricians, only 56% (380/674) knew that children with epilepsy are at an increased risk of sudden unexplained death compared to children without epilepsy. Only 33% (225/674) of paediatricians caring for children with epilepsy were aware of the term SUDEP.

Fourteen paediatricians reported knowledge of a case of SUDEP. Of the 11 cases for which details of the death investigation process were reported, five children (45%) did not undergo autopsy, suggesting inadequate investigation of deaths in children with epilepsy. The survey methodology does not permit accurate incidence calculations.

This survey identifies poor awareness of SUDEP among Canadian paediatricians and highlights the need for educational initiatives to support future studies involving SUDEP case collection. Accurate incidence data will require prospective surveillance of SUDEP in children. More information about SUDEP may be found at www.sudepaware.org.

1 Principal investigator
Elizabeth J. Donner, MD, FRCPC, Division of Neurology, University of Toronto, The Hospital for Sick Children, Toronto ON M5G 1X8; tel.: 416-813-7037; fax: 416-813-6334; elizabeth.donner@sickkids.ca
International Developments

The International Network of Paediatric Surveillance Units (INoPSU), established in 1998, continues to enhance collaboration between national paediatric surveillance units. Currently, there are 12 national paediatric surveillance units worldwide that are full members of INoPSU: Australia, Britain, Canada, Cyprus/Greece, Germany, Ireland, Latvia, Netherlands, New Zealand, Portugal, Switzerland and Wales. The British Ophthalmological Surveillance Unit is an associate member, and the Belgian Paediatric Surveillance Unit is an affiliate member.

2011 highlights

The 7th INoPSU meeting was held in Montreux, Switzerland on September 1–2, 2011, and coincided with the Swiss Paediatric Society scientific meeting. Seventeen representatives from eight different INoPSU units were present (www.inopsu.com). The two-day meeting comprised a one-day scientific meeting, followed by the INoPSU business meeting.

The scientific program included the following presentations:

- The Swiss Paediatric Surveillance Unit: highlights of 15 years of operation
- The Belgian Paediatric Surveillance Unit “PediSurv”
- The BPSU: 25 years of informing vaccination policy
- The importance of engaging with patient support groups: education, research and influencing national policy on rare diseases in Australia
- Injuries associated with baby products, Canadian Hospitals Injury Reporting and Prevention Program (CHIRPP), and CPSP data results
- Alcohol coma admissions in the Netherlands
- The 3rd national survey on childhood celiac disease in the Netherlands: still changing epidemiology and clinical presentation
- Haemolytic uraemic syndrome in Switzerland: twelve years prospective surveillance
- Guillain-Barré/Fisher syndrome surveillance in the UK: is there a temporal association with influenza infection or vaccination?
- Vitamin D deficiency rickets in Australia: need for screening and early treatment in high risk groups
- Can active surveillance improve reporting of serious and life-threatening adverse drug reactions? The CPSP experience
- Severe hyperbilirubinaemia of the newborn: a problem in Switzerland?
- A lasting legacy? A BPSU study case review to evaluate public health impact

The business meeting focused on the roles of INoPSU, its benefits to members and the importance of good governance and financial accountability. The request for membership by the Belgium Paediatric Surveillance Unit was approved and the unit was formally welcomed to INoPSU. The network now has added a third level of membership, “associate,” to the two current levels, full and affiliate. The new level will allow individuals and groups who have an interest in rare paediatric conditions to join INoPSU. Other INoPSU decisions include affirming BPSU as the administrative centre, re-developing the website, raising the profile of activities and producing collaborative international publications. Yvonne Zurynski from Australia and Danielle Grenier from Canada are the INoPSU co-chairs.

The 8th INoPSU meeting celebrating the 15th anniversary of the Australian Paediatric Surveillance Unit will be held in conjunction with the International Paediatric Congress (www.ipa-world.org) in Melbourne, Australia, August 24–29, 2013.
International Developments

Publications from INoPSU members

Australian Paediatric Surveillance Unit (APSU)


Lim A, Cranswick N, South M. Adverse events associated with the use of complementary and alternative medicine in children. Arch Dis Child 2010. doi:10.1136/adc.2010.183152

British Paediatric Surveillance Unit (BPSU)


Further publications can be found at www.inopsu.com.
RESEARCH OPPORTUNITIES

Call for New Studies

Wanted
Investigators to initiate new CPSP studies

The program
• Well established, timely and cost-effective
• Multi-faceted surveillance, capable of collecting reliable data in a variety of fields
• Effective at monitoring low-frequency, high-impact diseases and conditions

Track record
• 79% response from approximately 2,500 paediatricians
• 85% data completion rate

Study ideas
• Adverse neonatal outcomes of delivery or labour in water
• Bronchiectasis – non-cystic fibrosis
• Celiac disease
• Chylothorax
• Congenital syphilis
• Cyberbullying
• End-stage renal disease in early infancy
• Gonorrhea, syphilis, chlamydia and trichomonas infections
• Group A streptococcal toxic/septic shock
• Hallucinations with psychostimulants
• Hypercalcemia/nephrocalcinosis
• Life-threatening and lethal poisoning
• Marijuana-induced psychosis
• Moderate and severe encephalopathy
• Polyposis syndromes in children
• Systemic lupus erythematosus
• Tick-borne encephalitis
• Underdiagnosed cyanotic congenital heart disease

If you are interested in these or other studies, or for more program information, please contact 613-526-9397 ext. 239 or e-mail cpsp@cps.ca.

“Fifteen years of success and still growing and improving! Over the years the CPSP has become an important collaborative tool for research, health policy development and the active surveillance of less common paediatric disorders. The hundreds of Canadian child care specialists who participate monthly in the program ensure that the CPSP is an effective way to foster continuing medical education on a wide spectrum of clinical conditions that might otherwise go largely unrecognized.”

Dr. Bryce Larko, past Chief Medical Officer of Health, Whitehorse, Yukon Territory, and past member of the CPSP Steering Committee from 2004 to 2010
eCPSP

Improving paediatric surveillance

Launched November 2011

eCPSP is

- Greener
- Simple – a monthly hyperlink is sent to you
- Safe and secure – data is fully encrypted and hosted in Canada
- Easy – no log-in or passwords are required
- Accessible – reporting is possible from anywhere you have Internet access
- Quick – instant access to case definitions and full protocols
- Timely – receive detailed questionnaires much sooner

Update

As of May 1, 2012:
- There are 1,278 (49%) online participants
- 47% online participants report the first day they receive the e-mail

Next phases

- Performance monitoring
- Recruitment of off-line participants to online reporting
- Development of online one-time surveys
- Development of online detailed questionnaires

If you are not already signed up as an online participant, please switch today!
E-mail us at cpsp@cps.ca and provide your preferred e-mail address.
For more information on the Canadian Paediatric Surveillance Program or a French version of this report, please contact:

Canadian Paediatric Society
Melanie Laffin Thibodeau, Manager, Surveillance
2305 St. Laurent Blvd.
Ottawa ON K1G 4J8
Tel.: 613-526-9397, ext. 239
Fax: 613-526-3332
cpsp@cps.ca
www.cps.ca/cpsp

Canada Post Publications Agreement number 40006512